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Abstract 
The striatal neuronal populations comprise medium spiny projection neurons (MSNs) and GABAergic 
and cholinergic interneurons. Huntington’s disease (HD) involves massive degeneration of striatal 
neurons. The derivation of MSNs and interneurons from human pluripotent stem cells (hPSCs) would 
allow modelling of striatal function and HD in vitro, as well as provide a viable source of tissue for cell 
replacement therapy.  
Our lab has previously demonstrated that Activin A can induce MSN fate in hPSCs, and that these cells 
can survive and differentiate in vitro and in vivo. In this study, it was found that this effect occurs via 
the Activin receptor, independently of SHH signalling. Furthermore, blockade of BMP signalling 
accelerated MSN differentiation. Electrophysiological analysis demonstrated their potential to acquire 
functional membrane properties and synaptic activity in vitro. 
Wnt inhibition and SHH activation have been shown to pattern hPSCs into medial ganglionic eminence 
(MGE) progenitors and cortical interneurons. Both cortical and striatal interneurons are born in the 
MGE. This thesis presents the first account of generating MGE progenitors for the purpose of 
producing striatal interneurons in vitro. They expressed subtype markers such as parvalbumin, 
somatostatin, calretinin and choline acetyltransferase. When transplanted into neonatal rat striatum, 
hPSC-derived MGE progenitors migrated to the septum and hippocampus within 6 weeks. The 
majority of differentiated neurons became calretinin GABAergic interneurons, and a few in the 
striatum acquired cholinergic interneuron fate. Patch clamp analysis both in vitro and in vivo revealed 
functional neuronal characteristics and synaptic connectivity, although a more mature neuronal 
phenotype was achieved in vivo. 
In conclusion, functional striatal MSNs and interneurons can be generated using hPSCs, which will be 
invaluable for research into striatal function and dysfunction in HD and other striatum relevant 
disorders. They may also serve as a desperately needed therapy for HD, pending further preclinical 
studies in HD animal models. 
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1 
1 Introduction 
1.1 The striatum and Huntington’s disease 
1.1.1 Striatal anatomy and function 
The striatum is the main input nucleus of the basal ganglia, an assembly of subcortical nuclei involved 
in the control of voluntary actions, reward and habit formation. The dorsal striatum is the largest part 
and comprises the caudate and putamen, which regulate the motor and associative roles of the 
striatum. The ventral striatum includes the nucleus accumbens and olfactory tubercle, which also form 
part of the limbic system and reward pathways. The basal ganglia circuit is a complex feedback loop 
with the cortex and thalamus that processes motivation and reward levels to filter out unnecessary 
actions and allow purposeful actions. The model by which this is widely agreed to occur is based 
around the two distinct populations of striatal projection neurons, or medium spiny neurons (MSNs), 
which form the direct and indirect pathways through the basal ganglia (Bolam et al., 2000).  
MSNs are GABAergic projection neurons making up 75% and 95% of striatal neurons in primates and 
rodents respectively. The remainder of striatal neurons are GABAergic and cholinergic interneurons 
(Wu and Parent, 2000). MSNs are identified by their expression of the dopamine- and cAMP-regulated 
phosphoprotein (DARPP32), which is involved in integrating dopamine and NMDA receptor signalling. 
This is a crucial function in MSNs, as they receive strong glutamatergic innervation from the cortex 
and thalamus, and dopaminergic input from the substantia nigra pars compacta (SNc). MSNs can 
belong to either the direct or indirect pathway, and can be distinguished by their connectivity, 
dopamine receptor expression and anatomical location. Direct pathway MSNs express D1 dopamine 
receptors and substance P, and innervate the substantia nigra pars reticulata (SNr) and the internal 
segment of the globus pallidus (GPi; or entopeduncular nucleus in rodents). MSNs of the indirect 
pathway express D2 dopamine receptors and enkephalin, and project to the external segment of the 
globus pallidus (GPe). These two populations are also largely anatomically segregated, with direct 
pathway MSNs concentrating in the striosomal (patch) compartments and indirect pathway MSNs 
assembling in the matrix (Davis and Puhl, 2011). The SNr and GPi are the basal ganglia output nuclei, 
populated with GABAergic projection neurons that innervate the thalamus. The GPe is an intermediate 
nucleus that sends inhibitory projections to the SNr and GPi, as well as the subthalamic nucleus (STN) 
(Bolam et al., 2000). Another pathway was proposed by Nambu et al. to send even faster excitation 
from the cortex to the GPi and SNr via the STN, which they termed the hyperdirect pathway (Nambu, 
Tokuno and Takada, 2002). 
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Using movement as an example of the behavioural output controlled by the basal ganglia, at rest the 
GPi and SNr are tonically active while MSNs are quiescent. Upon excitatory input from the motor 
cortex, direct pathway activation causes inhibition of the GPi and SNr, and disinhibition of the 
thalamus, promoting movement. Activation of the indirect pathway however, inhibits the GPe, 
disinhibiting the GPi and SNr, allowing inhibition of the thalamus and suppressing motor output. The 
excitability of the two opposing MSN groups is constantly modulated by dopaminergic input from the 
SNc, which increases excitability of D1-expressing MSNs and decreases excitability of D2-expressing 
MSNs (Beaulieu and Gainetdinov, 2011) (Figure 1.1). Meanwhile, the hyperdirect pathway activates 
GPi and SNr neurons to inhibit the thalamus and suppress movement. It is thought that together, these 
pathways work in a specific spatiotemporal manner to disinhibit a specific population of output 
neurons while inhibiting the surrounding cells, such that a specific action is permitted (Nambu, Tokuno 
and Takada, 2002). This classical model of basal ganglia function has come under recent scrutiny based 
around the antagonistic and parallel nature of the two striatal pathways (Calabresi et al., 2014). 
Rather, in light of recent evidence showing the expression of heteromeric complexes of D1 and D2 
dopamine receptors in MSNs of both pathways, Calabresi et al. have proposed a revised model in 
which the pathways work together in constant communication to initiate and stop movement 
(Calabresi et al., 2014). Cholinergic and GABAergic interneurons synapse onto MSNs of both pathways 
as well as dopaminergic axons, facilitating synaptic plasticity. 
This revised model provides well-deserved acknowledgement of the role of striatal interneurons in 
striatal function. Striatal interneurons fall into several categories based on neurotransmitters, 
molecular markers and firing properties. Cholinergic interneurons are identified chemically by their 
expression of choline acetyltransferase (ChAT) and are tonically active. They were known to play a role 
in reward and associative learning, and their activation was shown to cause inhibitory currents in 
MSNs. The mechanism behind this was recently found to be that they synapse directly onto 
dopaminergic axons, stimulating action potential-independent release of dopamine and GABA onto 
MSNs (Threlfell et al., 2012; Nelson et al., 2014). GABAergic interneurons can be further subdivided 
into those that express parvalbumin (PV), somatostatin (SST) and calretinin (CR). PV interneurons 
receive direct glutamatergic input from cortical neurons and synapse onto MSNs, providing feed 
forward inhibition. Their electrophysiology is characterised by extremely fast spiking and narrow 
action potentials (Plotkin et al., 2005). SST-expressing interneurons are also often referred to by other 
markers that are co-expressed in the majority of this subtype: neuropeptide Y (NPY), nitric oxide 
synthase (NOS) or NADPH-diaphorase (Figueredo-Cardenas et al., 1996). In addition to GABA release 
near MSN dendritic spines, these cells have been shown to release nitric oxide (NO) following 
simultaneous glutamate and dopamine receptor activation, which diffuses into MSN dendrites and 
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reduces their excitability (Fino and Venance, 2011). Strangely, there have been no studies that have 
matched electrophysiological analysis with post-hoc identification of calretinin-expressing striatal 
interneurons, leaving their role in striatal function somewhat elusive.  
Notably, most research on striatal interneurons has been done in rodents, and from numbers alone it 
is clear that they have substantial differences to primate striatal interneurons. In particular, 
interneurons make up 23% of primate striatal neurons, and only 5% in rodents. Furthermore, in the 
rat striatum, PV interneurons are the most abundant, with about the same numbers of CR and SST-
expressing cells (PV:CR:SST, 4:3:3), while in primates there are more than double the proportion of CR 
interneurons over PV or SST (Wu and Parent, 2000). This shows how more research into human and 
primate striatal interneurons is necessary to better understand their physiological function. 
 
Figure 1.1: Schematic diagram of classical direct/indirect pathway model of basal ganglia organisation and 
function. 
Cortical input to the striatum activates the GABAergic direct and indirect pathways, which are modulated by 
dopaminergic innervation from the SNc. At rest, the GPi and SNr tonically inhibit the thalamus. Upon cortical and 
SNc activation, the direct pathway inhibits the GPi causing disinhibition of the thalamus. Meanwhile the indirect 
pathway is inhibited by SNc input to cause further inhibition of the GPi. The hyperdirect pathway proposed by 
Nambu et al. (2002) is an excitatory projection from the cortex via the STN that stimulates the output nuclei to 
exert inhibition on the thalamus. D1/D2 = dopamine receptors; SNc/r = substantia nigra pars 
compacta/reticulate; GPe/i = globus pallidus externa/interna; STN = subthalamic nucleus. 
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1.1.2 Huntington’s disease 
Huntington’s disease (HD) is a progressive neurodegenerative disorder caused by an inherited 
cytosine-adenine-guanine (CAG) repeat in the Huntingtin (HTT) gene. This autosomal dominant 
mutation produces a poly-glutamine stretch in the HTT protein giving it gain-of-function that is 
particularly toxic to neurons (MacDonald et al., 1993). Despite its ubiquitous expression, striatal MSNs 
are by far the most susceptible to the excitotoxicity caused by HTT, but the mechanism behind this is 
unclear. Although cortical grey matter volume is reduced by around 23%, the caudate and putamen 
show the largest reduction in volume, between 46 and 62% (Monte, Vonsattel and Richardson, 1988; 
Halliday et al., 1998). This was found to be relatively specific to MSNs, while striatal interneurons were 
thought to be largely spared. Indeed, MSNs in the rat striatum were found to express endogenous Htt 
at much higher levels than any of the interneuron subtypes (Kosinski et al., 1997). The different MSN 
populations were found to be differentially affected in human patients, particularly in the early stages 
of HD, in which the abundance of indirect pathway enkephalin-positive fibres was reduced to 34% of 
those in control brains, while substance P-positive fibres of the direct pathway were only reduced to 
71% (Deng et al., 2004). At the latest stage of HD however, both populations were reduced to less 
than 10% of controls. The early loss of indirect pathway MSNs is believed to cause the involuntary 
movements associated with chorea, one of the most prominent motor symptoms of HD (Starr et al., 
2008). Later loss of the direct pathway MSNs results in bradykinesia and rigidity. Before onset of motor 
symptoms, psychiatric and cognitive deficits can go unnoticed for years before diagnosis, and manifest 
as increased irritability and impaired executive functions such as planning and organisation (Ross and 
Tabrizi, 2011). These impairments are also caused by striatal degeneration and its usual rich 
innervation of the prefrontal cortex and limbic system. 
Due to the established vulnerability of MSNs, striatal interneurons are often dismissed when 
discussing HD pathogenesis as “selectively spared” (Ross and Tabrizi, 2011). However, in rodent 
models, PV interneurons were shown to contain Htt-positive intranuclear inclusions in the R6/2 HD 
transgenic mouse model and a reduction in phosphorylated CREB in quinolinic acid-lesioned rats 
(Kosinski et al., 1999; Giampà et al., 2006). Reiner et al. compared healthy brains with the brains of 
HD patients spanning all 4 symptomatic grades as defined by Vonsattel et al. (Vonsattel et al., 1985; 
Reiner et al., 2013). At grade 1 there is little atrophy but moderate astrocytosis and loss of 50% of 
striatal neurons; by grade 4, more than 95% of neurons are lost causing massive striatal atrophy and 
enlargement of the lateral ventricles, as well as marked atrophy of the globus pallidus (Vonsattel et 
al., 1985). Reiner et al. showed that PV interneurons are significantly reduced in the rostral caudate 
at grade 1, and all over the striatum by more than 80% at the latest stages of the disease, which is 
unsurprising considering the 95% neuronal loss characterised at grade 4 (Reiner et al., 2013). The PV 
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interneuron loss is thought to have a profound impact on the types of motor symptoms experienced 
around grade 3, which typically sees a transition from chorea to dystonia. Other striatal interneurons 
have been confirmed several times to resist degeneration in HD, although the large cholinergic 
calretinin-expressing interneurons have been shown to downregulate ChAT and calretinin expression 
rather than degenerate, which is still likely to impact their function (Massouh et al., 2008). Going 
forward, it will be important to consider all striatal cell types when conducting research into HD 
pathophysiology. 
There are currently no disease modifying drugs available for HD, and all treatment is aimed at relieving 
the myriad of symptoms. Motor symptoms such as chorea, myoclonus, dystonia and rigidity can be 
treated with anticonvulsants, levodopa, benzodiazepines and muscle relaxants, but these drugs have 
their own debilitating side effects such as depression, sedation or causing an opposite motor 
symptom. Neuroleptics and anti-depressants are often used to treat the psychosis, depression and 
anxiety, causing a whole host of sympathetic nervous system-related side effects (Ross and Tabrizi, 
2011). However, symptomatic treatment of HD does not provide any increase to lifespan compared 
to patients in parts of the world where medical treatment is unavailable (Walker, 2007). The full 
penetrance and hereditary nature of the disease means that preventative measures would be 
relatively easy to administer in future generations, but more needs to be known about the 
mechanisms by which mutant HTT causes HD for this to become a reality. Because currently diagnosis 
usually occurs once striatal degeneration is already well under way, novel therapies must also aim to 
repair the lost striatal circuitry, or at least cease any further damage. 
1.1.2.1 Disease mechanisms 
The Huntingtin protein is expressed in all mammalian cells, but despite the discovery of the HTT gene 
more than 20 years ago, its physiological function remains relatively unknown (MacDonald et al., 
1993). It is a largely cytoplasmic protein that occasionally translocates to the nucleus, it has a role in 
vesicular transport and gene transcription, and may also regulate trafficking of RNA (Ross and Tabrizi, 
2011). Homozygous Htt deletion is embryonically lethal in animals, whereas heterozygous knockouts 
develop normally (Nasir, Floresco and O’Kusky, 1995). This opposes the view that HD could be caused 
by HTT loss-of-function in one allele, and supports the growing consensus that HTT gain-of-function is 
toxic to cells. Furthermore, it has been shown that the number of CAG repeats, and therefore the 
polyglutamine length, is inversely associated with the age of HD onset (Andrew et al., 1993). 
Polyglutamine aggregates are formed in vitro when there are more than 36 consecutive glutamine 
residues on a protein, which lines up with the finding that HD only manifests itself in people with 36 
or more CAG repeats (Walker, 2007). The mechanisms by which mutant HTT causes HD are many and 
diverse, from truncated toxic N-terminal fragments and abnormal aggregate formation, to changes in 
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gene transcription and impaired cell metabolism (see Ross and Tabrizi (2011) for review of 
mechanisms). 
These varied pathways result in selective early degeneration of striatal MSNs, thought to be mediated 
by their susceptibility to excitotoxicity from cortical and thalamic innervation and their rich expression 
of glutamate receptors. Specifically, one proposed mechanism of HD is that reduced glutamate uptake 
by astrocytes leads to increased glutamate at corticostriatal synapses, causing overstimulation of 
NMDA receptors and excessive calcium ion influx (Figure 1.2) (Ross and Tabrizi, 2011; Schwarcz et al., 
2011). Brain-derived neurotrophic factor (BDNF) is one gene of interest whose expression is reduced 
in HD patients. MSNs and PV interneurons are particularly dependent on BDNF, released from 
corticostriatal neurons, for neurotrophic support and maintenance of GABAergic synapses (Ghiglieri 
et al., 2012). Another gene whose transcription is altered in HD is NF-κB, which regulates the 
expression of many pro-inflammatory cytokines, causing microglia to become activated and the 
presence of more reactive oxygen species, increasing levels of oxidative stress and perpetuating the 
excitotoxicity in MSNs (Ross and Tabrizi, 2011). Inflammation is likely to have a far more important 
role in striatal degeneration than previously thought. The striatum is the only region in HD that 
undergoes reactive astrocytosis, giving an indication as to why the striatum might be the most affected 
(Vonsattel and Difiglia, 1998). Furthermore, innate immune activation was detected in subjects 
carrying the HD mutation 16 years prior to predicted onset of clinical symptoms, heavily implicating 
cell-autonomous immune activation as a mechanism for causing striatal degeneration (Björkqvist et 
al., 2008). 
 
Figure 1.2: Potential intracellular mechanisms of HTT-induced pathology in HD. 
Mutant HTT causes reduced BDNF release from cortical projection neurons. Glutamate uptake by astrocytes is 
impaired and activated microglia release quinolinic acid, causing increased NMDA receptor activation on MSNs 
and excitotoxicity. 3HK=3-hydroxykynurenine. QUIN=quinolinic acid. KMO=kynurenine 3-monooxygenase. 
ROS=reactive oxygen species. Trk B=tyrosine kinase B receptor. NMDA=N-methyl-D-aspartic acid. From Ross and 
Tabrizi (2011). 
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1.1.2.2 Animal models 
HD is a strictly human disease, so any attempts to model the disorder in vivo must be induced in the 
animals, mostly rodents, and this has been done either genetically or by lesioning the striatum with 
an excitotoxin. There are many different transgenic mouse models with broadly three types of 
mutation (Ferrante, 2009). First, those that express the N-terminus of the human HTT gene containing 
the CAG repeats, for example the R6/2 mouse, which is one of the most widely used and displays 
progressive neurodegeneration and behavioural impairment that resembles HD, with a shortened 
lifespan of 14 to 21 weeks. Second, mice that have extra CAG repeats inserted into their own Htt gene, 
which may in theory be more genetically accurate but in reality produces a much subtler phenotype. 
The HdhQ111 mouse has a normal lifespan, but does encounter MSN-specific neuropathology and 
late-onset motor deficits. Thirdly, yeast or bacterial artificial chromosomes (YAC/BAC) have been 
employed to express the full-length human mutant HTT in mice, and show behavioural and cognitive 
deficits similar to HD patients, as well as striatal degeneration. Transgenic mouse models have been 
invaluable in researching the cellular mechanisms of HD and investigating potential therapeutic 
mechanisms. 
Excitotoxic lesion models aim to recreate MSN-specific degeneration by injecting an excitotoxin 
directly into the striatum, to which MSNs are more vulnerable than other neurons or glial cells. By far 
the most commonly used excitotoxin for this approach is quinolinic acid (QA), a NMDA receptor 
agonist. QA is an endogenous metabolite in the kynurene pathway, which has been shown to be over-
activated in the microglia of 3 different transgenic mouse models and early grade (0/1) HD patients, 
when there is marked neuronal loss but little macroscopic change to the striatum (Figure 1.2) (Guidetti 
et al., 2004, 2006). QA injected intrastriatally had previously been shown to specifically target MSNs, 
sparing large cholinergic interneurons, glia and afferent axons from the cortex and thalamus (Roberts 
et al., 1993). However, there has been much conflicting evidence on whether the GABAergic 
interneurons are spared or also killed by QA. SST interneurons were severely depleted in many studies, 
but this effect differed greatly depending on the type of analysis conducted and the age of the rats 
receiving the injection (Roberts et al., 1993; Figueredo-Cardenas, Chen and Reiner, 1997). PV 
interneurons have been less widely analysed, but were reduced comparatively to MSNs in one study 
and selectively spared with cholinergic interneurons in another (Figueredo-Cardenas et al., 1998; Liang 
et al., 2005). The massive neuronal loss caused by QA in rodents provides a robust model of the later 
stages of HD, displaying severe motor and cognitive impairments, allowing the testing of reparative 
therapeutic strategies to replace lost striatal neurons or to protect those that do survive the insult. 
Furthermore, excitotoxin-induced lesions delivered the only non-human primate HD models until 
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recent advances in genetic primate models, providing a more human-related model on which to test 
new therapies before going into clinical trials (Ghiglieri et al., 2012). 
1.1.2.3 Cell replacement therapy 
Brain repair by cell replacement therapy has long been a suggested therapeutic strategy, stemming 
from the use of foetal ventral midbrain tissue to replace lost nigral dopaminergic cells in Parkinson’s 
disease (PD) (Björklund and Stenevi, 1979; Björklund et al., 2003). The success of in vivo studies in this 
area prompted the suggestion that the same could be applied to HD by isolating whole ganglionic 
eminence (WGE), the developmental birthplace of striatal neurons, from foetuses and transplanting 
it into the striatum of lesioned animal models or human patients. This was understood to be a bigger 
challenge than PD due to the complex circuitry to which the striatal MSNs belong as well as the 
comparatively long distances travelled by MSN axons (Peschanski, Cesaro and Hantraye, 1995). Initial 
studies grafting rat foetal WGE into excitotoxin-lesioned rat striatum gave promising histological 
results, showing formation of MSN-rich P-zones that expressed typical mature striatal molecular 
markers (Graybiel, Liu and Dunnett, 1989). There was also good evidence showing formation of 
afferent connections from the relevant host cortical and subcortical regions, as well as efferent 
connections from the graft to the globus pallidus (Wictorin et al., 1988, 1989; Wictorin and Björklund, 
1989). Behavioural studies using sensitive motor testing have shown that allografts can restore motor 
impairment in the lesioned rats (Döbrössy and Dunnett, 2005; Klein, Lane and Dunnett, 2012). 
Importantly, ex vivo brain slice recordings from grafted cells have demonstrated functional integration 
of the cells through long term potentiation and depression from corpus callosum stimulation 
(Mazzocchi-Jones, Döbrössy and Dunnett, 2009, 2011). This supports the idea that grafts are not just 
producing neurotrophic factors aiding the remaining host neurons, but are in fact restoring striatal 
circuitry. Xenografting of human foetal tissue into rodent HD models has been vital for the progression 
of the technique towards clinical trials. However, human tissue grafts appear to take as long to mature 
as in normal development, perhaps explaining the reduced P zone formation and limited behavioural 
recovery when compared with rat WGE grafts (Grasbon-Frodl et al., 1996; Pundt et al., 1996; Sanberg 
et al., 1997; Lelos et al., 2015). The most promising results have come from allografting studies of non-
human primate WGE into excitotoxin-lesioned monkeys, causing recovery of skilled motor function 
up to 7 months post-transplantation (Kendall, Rayment and Torres, 1998; Palfi et al., 1998). 
On the basis of the successful allografting studies in rodents and non-human primates, clinical trials 
transplanting human WGE into HD patients was approved in several centres around the world (Kopyov 
et al., 1998; Bachoud-Lévi et al., 2000; Rosser et al., 2002). The principal aim of these trials was the 
safety and tolerability of intrastriatal transplantation with foetal WGE tissue. While there were small 
improvements in motor and cognitive symptoms in 3 of 5 patients until 2 years post-transplantation 
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in the French trial, this effect had disappeared by 4-6 years (Bachoud-Lévi et al., 2006). The NEST-UK 
trial followed up 3-10 years post-transplantation and similarly showed no significant differences on 
any measure between patient groups (Barker et al., 2013). However, there were no foetal tissue graft-
related adverse events in these studies, and the number of cells transplanted was considered quite 
small for any functional improvement to occur. Post-mortem analyses of 6 and 18 month old grafts 
has confirmed the presence of DARPP32-positive neurons as well as SST and CR interneurons, TH fibre 
innervation and lack of mutant HTT in grafted cells (Freeman et al., 2000; Capetian et al., 2009). 
Around 10 years after transplantation, post mortem grafts still showed the presence of P-zones with 
MSNs and interneurons, but there was also evidence of MSN-specific degeneration and  fewer blood 
vessels throughout the graft area than the surrounding host tissue (Cicchetti et al., 2009; Cisbani et 
al., 2013). Overall, the clinical trials have demonstrated the safety of the procedure, and opened up 
the possibility to transplant more tissue in following trials, possibly subject to further optimisation of 
the graft composition (Barker et al., 2013). On the point of graft composition, the vast majority of 
preclinical studies have been done using WGE tissue. A handful of studies have either used only lateral 
GE (LGE) or compared it with medial GE grafts (MGE; striatal MSN or interneuron birthplaces 
respectively). While one study suggested that the greater the number of DARPP32-positive cells the 
better the functional recovery, others found that the presence of MGE tissue in the WGE grafts gave 
better overall survival as well as added functional benefits (Nakao et al., 1996; Grasbon-Frodl et al., 
1997; Watts, Brasted and Dunnett, 2000).  
The high quantity of tissue needed per graft in HD patients (5 WGEs per transplanted hemisphere), 
the very limited supply of viable foetal tissue from abortions and the lack of quality control possible 
on the tissue, all mean that it is not a feasible source of tissue for widespread treatment of HD. 
Therefore, clinical trials and in vivo studies using foetal tissue must act as a proof-of-principle, while 
another source of tissue is found. Recent advances in human pluripotent stem cell (hPSC) 
differentiation have made them a strong contender to replace foetal tissue. It is now possible to direct 
their differentiation towards a MSN fate, both in vitro and after transplantation into HD models (Aubry 
et al., 2008; Ma et al., 2012; Carri et al., 2013; Nicoleau et al., 2013; Arber et al., 2015). However, if 
WGE is the gold standard against which to compare, hPSC-derived grafts will likely require 
interneurons and perhaps glial cells in addition to MSNs to produce a functional graft. 
1.1.2.4 Novel therapeutic strategies 
It has been 23 years since the mutant HTT gene was discovered to cause HD, but despite this, disease-
modifying drug targets have been slow to emerge. Novel drug targets include lowering HTT levels in 
cells by RNA interference, antisense oligonucleotides or zinc finger proteins to lower mutant HTT 
transcript levels (Harper et al., 2005; Garriga-Canut et al., 2012; Kordasiewicz et al., 2012). Reduction 
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in mutant HTT has led to improvements in behavioural impairments but mostly when given early in 
the modelled disease. However, delivery of these potential therapies would need to be frequent and 
direct into the brain as they are unable to cross the blood brain barrier, creating a technical challenge 
that requires novel delivery methods. A pharmacological approach to this idea is inhibition of sirT1, a 
sirtuin deacetylase whose inhibition has been demonstrated to cause a selective decrease in mutant 
HTT. A clinical trial testing the effects of Selisistat, a SirT1 inhibitor, in HD patients has confirmed that 
it is safe and well tolerated (Süssmuth et al., 2015). Despite showing no signs of clinical benefit or 
effects on mutant HTT blood levels, biological samples were collected with the aim of developing 
SirT1-specific assays that will aid future trials. 
BDNF or other neurotrophic factor administration targeting the brain is an avenue that has shown 
promise in vivo. These are administered by gene therapy or synthetic polymer implants into the 
striatum, promoting survival of the remaining striatal neurons (Géral, Angelova and Lesieur, 2013). Of 
relevance to Chapter 3 is that administration of intrastriatal Activin A significantly reduced neuronal 
loss following QA lesion in rats, demonstrating neurotrophic effects on striatal neurons (Hughes et al., 
1999). A phase I clinical trial tested implantation of a device containing BHK cells (baby hamster 
kidney) programmed to release ciliary neurotrophic factor (CNTF) in the striatum of HD patients (Bloch 
et al., 2004). Although no clinical benefit was seen over the 2 years, the technique was deemed safe 
and feasible, and did show improved electrophysiological measurements in half the patients. Another 
delivery method is transplantation of genetically engineered mesenchymal stem cells to secrete BDNF 
that is being proposed for a Phase I clinical trial following their demonstration of safety and tolerability 
in trials for other diseases (Deng et al., 2016). Pharmacological increase in BDNF levels may be 
achieved using fingolimod, an approved therapy for multiple sclerosis that has a number of effects 
including immune modulation, MAP kinase activation, increased BNDF production and reduced 
NMDA-mediated excitotoxicity. Fingolimod has been shown to improve motor function and reduce 
brain atrophy in the R6/2 mouse model, promising findings suggesting it could be clinically beneficial 
in HD patients (Di Pardo et al., 2014). 
Deep brain stimulation (DBS) is a surgical approach based on the findings that pallidotomy could be 
beneficial for dystonia and chorea in HD. Long term follow up of patients with GPi DBS showed 
significant improvement of chorea in all patients but had no effect on bradykinesia or dystonia 
(Gonzalez et al., 2014). It will be important to measure quality of life outcomes in these studies in 
order to evaluate the long term benefits of such therapies. 
Overall, cell replacement therapy is by far the most thoroughly researched potential therapy for HD 
and does hold promise for reversing the impact of striatal degeneration. However, more easily 
11 
administered pharmacological approaches that can inhibit the toxic actions of mutant HTT earlier in 
the disease would be the ideal early intervention. 
1.2 Striatal development 
1.2.1 Neural induction 
Gastrulation of the embryo leads to the formation of the three germ layers – ectoderm, mesoderm 
and endoderm. The innermost layer, the endoderm, forms the respiratory and gastrointestinal tracts. 
The mesoderm is the middle layer and becomes tissues such as muscle and cartilage. Finally, the outer 
layer, the ectoderm, gives rise to the hair, skin, sweat glands and nervous system. A dorsal part of the 
mesoderm forms Spemann’s Organiser region, first discovered in 1924 by Spemann and Mangold. 
They transplanted what is now known as the Organiser region from a Xenopus embryo onto the 
ventral side of another embryo, causing the formation of 2 separate neural axes, demonstrating that 
this region alone is enough to trigger neural induction (Spemann and Mangold, 1924). Later, the key 
morphogens that were discovered to be released from the Organiser were identified as noggin, 
chordin and follistatin, which act by inhibiting BMP and TGFβ signalling that induce endoderm and 
mesoderm in the adjacent tissues (Smith and Harland, 1992; Hemmati-Brivanlou, Kelly and Melton, 
1994; Sasai et al., 1994; Zimmerman, De Jesús-Escobar and Harland, 1996; Bachiller et al., 2000). The 
equivalent structure in mouse was termed the “node”, but was found to only induce posterior 
structures and lacked the anterior forebrain. In mammals, the anterior visceral endoderm (AVE) is also 
required for telencephalon formation (Tam and Steiner, 1999; Andoniadou and Martinez-Barbera, 
2013). Over time, the central notochord arises from the cells of the Organiser as the embryo elongates 
along the rostro-caudal axis, and the neural plate overlying the notochord folds inwards to create the 
neural tube in a process called neurulation. Depending on the dorso-ventral and rostro-caudal location 
along the neural tube, cells release and are exposed to different levels and types of morphogens, 
which play a key role in instructing cell fate (Bronner-Fraser and Fraser, 1997). 
The notochord releases a morphogen called Sonic hedgehog (SHH), exposing cells all along the ventral 
neural tube to high concentrations of this protein (Rubenstein et al., 1998). The caudal part of the 
neural tube forms the spinal cord, while more rostrally the hindbrain, midbrain and forebrain form 
distinct swellings in the neural tube. The forebrain is largely patterned by the anterior neural ridge 
(ANR), a patterning centre at the most rostral end of the neural plate that releases fibroblast growth 
factor 8 (FGF8) and Wnt inhibitor Dickkopf1 (DKK1) (Backman et al., 2005). Some of the relevant 
signalling pathways and morphogens involved specifically in forebrain development are described in 
the following sections. 
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1.2.2 Key morphogens and signalling pathways in forebrain development 
1.2.2.1 Sonic hedgehog (SHH) signalling 
Shh was discovered in mouse as one of three genes related to the Drosophila hedgehog gene, an 
important patterning factor in its development. Shh was found to be expressed in late stages of 
gastrulation, strictly in the midline, then extends along the entire notochord and head process. Its 
expression is then induced in the developing CNS, further than the rostral limit of the head process, 
where it spreads into the ventral forebrain and ventrolaterally in the midbrain. Expression is 
maintained in both the notochord and the floorplate midline along the hindbrain and spinal cord 
(Echelard et al., 1993). As indicated by its strict spatial expression profile, SHH signalling is heavily 
involved in dorso-ventral patterning of the neural tube, creating a morphogen gradient that patterns 
cells by concentration. 
Following release from ventral midline cells along the neural tube, SHH binds to the membrane 
receptor Patched (Ptc). In the absence of SHH, Ptc represses the G-protein coupled receptor (GPCR) 
Smoothened (Smo) while Gli(1-3) transcription factors are retained in a cytoplasmic pool. When SHH 
binds Ptc, the receptor is internalised and Smo is able to initiate an intracellular signalling cascade 
involving Gli proteins, which target Ptc and Gli genes in a feedback loop (Hooper and Scott, 2005; 
Traiffort, Angot and Ruat, 2010). Gli1 expression is consistently associated with SHH pathway 
activation and acts only as a transcriptional activator, therefore its ectopic expression mimics SHH 
expression (Hynes et al., 1997; Lee et al., 1997). Gli2 has a similar activating role to Gli1 but to a lesser 
extent (Ruiz I Altaba, 1998). In contrast, Gli3 appears to be downregulated by SHH signalling, and has 
a high propensity to form a protein kinase A (PKA)-dependent cleaved repressor version of itself 
(Gli3R) that forms an inverse gradient with SHH and represses its target genes (Figure 1.3) (Wang, 
Fallon and Beachy, 2000; Rallu et al., 2002). Indeed, in Shh knockout mouse embryonic telencephalon, 
dorsal markers spread to much of the ventral region, which loses its usual structure. In Gli3 knockouts 
the opposite is true – ventral markers are expressed in the dorsal regions, although some dorsal 
markers are still expressed. In mice lacking both Shh and one copy of Gli3, the dorso-ventral molecular 
profile is largely restored, with clear dorsal and ventral regions demarcated by their usual transcription 
factor expression profiles (Rallu et al., 2002). 
In this thesis, alongside recombinant SHH itself, Purmorphamine, a small molecule SHH agonist, is used 
that has been shown to activate SHH signalling by direct Smo activation (Sinha and Chen, 2006). The 
chemical inhibitor of SHH signalling used here, Cyclopamine, also binds Smo directly but suppresses 
its activity (Chen et al., 2002). 
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1.2.2.2 Wnt signalling 
Wnt signalling is crucial for telencephalic patterning. Initial antagonism of Wnt by DKK1 is key for 
inhibiting posterior patterning and establishing the telencephalon (Yamaguchi, 2001). Several Wnt 
genes are then expressed in the dorsal midline of the telencephalon where they regulate proliferation 
and specification of the developing cortex (Lee et al., 2000). Specifically, Wnt3a has been shown to 
induce dorsal markers such as Pax6, Ngn2 and Emx1 while suppressing the ventral marker NKX2.1 
(Gunhaga et al., 2003). 
Wnts are secreted glycoproteins and their signalling involves three main intracellular pathways: the 
canonical Wnt pathway, the Wnt/calcium ion pathway and the planar cell polarity pathway (Huelsken 
and Behrens, 2002). The canonical Wnt pathway has been shown to be active in the dorsal pallium 
and not at all in the subpallium, and indeed is required to suppress ventral cell fates in telencephalic 
development (Backman et al., 2005). Wnts bind to Frizzled (Frz) transmembrane putative GPCRs along 
with LRP co-receptors that are crucial for canonical signalling. In the absence of Wnt, β-catenin is 
phosphorylated and bound to a destruction complex including glycogen synthase kinase 3 β (GSK3β), 
axin and adenomatous polyposis coli (APC). This causes its ubiquitylation and degradation by the 
proteasome. When Wnts bind Frz, dishevelled (Dsh) prevents β-catenin degradation by removing 
GSK3β from the destruction complex. This allows β-catenin to enter the nucleus and interact with 
various transcription factors that upregulate Wnt target genes. The Wnt/Ca2+ pathway involves G-
protein activation of phospholipase C and protein kinase C (PKC), which leads to increased intracellular 
Ca2+ and calcineurin activation. Calcineurin dephosphorylates NF-AT, which suppresses canonical Wnt 
signalling in the nucleus. Finally, the planar cell polarity pathway recruits JNK and Rho-associated 
kinase (ROCK) for regulation of cytoskeletal organisation and polarity of cells (Huelsken and Behrens, 
2002). 
DKK1 blocks Wnt activity by inhibiting its binding to co-receptor LRP6 (Semenov et al., 2001). In this 
thesis, selective inhibition of canonical Wnt signalling is achieved using the small molecule XAV939, 
which is a tankyrase inhibitor, preventing the degradation of axin, thereby promoting persistence of 
the destruction complex and degradation of β-catenin (Huang et al., 2009). 
1.2.2.3 Transforming growth factor (TGF)-β family signalling 
The TGFβ superfamily of ligands is large and diverse, including two broad subfamilies according to 
their sequence similarity and binding receptors. The first subfamily includes TGFβs, Activins, and 
Nodal, and the second subfamily comprises bone morphogenetic proteins (BMPs), growth and 
differentiation factors (GDFs) and Muelerian inhibiting substance (MIS) (Shi and Massagué, 2003). 
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Between them, the superfamily of ligands have roles in regulation of cell proliferation, identification, 
differentiation and death, throughout embryogenesis as well as adulthood. 
The TGFβ ligands signal by binding to type I and II transmembrane receptor serine/threonine kinases, 
which phosphorylate intracellular receptor-regulated Smad proteins (R-Smad: 1/2/3/5/8). The R-Smad 
then forms a heteromeric complex with the Co-Smad, Smad4, and translocates to the nucleus where 
the complex interacts with other factors to alter gene transcription. Inhibitory Smads (I-Smad: 6/7) 
block TGFβ signalling by competing with R-Smads for receptor or Co-Smad binding (Massagué, 1998). 
TGFβ family ligands and receptors are summarised in Table 1.1. The TGFβ/Activin/Nodal subfamily 
ligands bind first to the type II receptor followed by recruitment of the type I receptor, typically 
ALK4/5/7, which phosphorylate Smad2/3 (Massague 1998 or Hart 2002). The BMP subfamily have 
higher affinity for the type I receptors (ALK2/3/6) so form first a complex with type I then type II 
receptors, leading to Smad1/5/8 phosphorylation (Kirsch 2000). 
There are many endogenous inhibitors of TGFβ family signalling, including noggin, chordin and 
cerberus, which inhibit BMPs by binding to its receptor binding sites, and follistatin, which does the 
same to Activins and BMPs (Shi and Massagué, 2003). The neural induction role of noggin, chordin 
and follistatin can be mimicked in vitro using small molecules LDN193189, dorsomorphin and 
SB431542, which are used throughout this thesis (Chambers et al., 2009; Boergermann et al., 2010). 
BMPs are the largest subfamily of TGFβ ligands and play an important role in dorso-ventral patterning 
of the telencephalon. They are expressed and secreted at the dorsal midline of the telencephalon, in 
regions corresponding to the future hippocampus and choroid plexus (Furuta, Piston and Hogan, 
1997). BMP-soaked beads reduced Shh expression by up to 96% in telencephalic explants, 
demonstrating that dorsalisation of chordin and noggin double mutants is due to an increase in BMP 
signalling (Anderson et al., 2002). This study also highlighted a role for noggin and chordin lasting 
beyond initial neural induction (Bachiller et al., 2000; Anderson et al., 2002). 
Activins (A/B/AB) have a less obvious role in forebrain development that requires some further 
research. Activin subunits and ActR-IIB were found to be expressed in the telencephalon of E12.5 
mouse embryos (Feijen, Goumans and van den Eijnden-van Raaij, 1994). Phosphorylated Smad2 was 
also found to co-localise with subpallial marker DLX2, and a direct upregulatory interaction was 
demonstrated using chromatin immunoprecipitation (ChIP) (Maira et al., 2010). These findings laid 
the foundation for the discovery in our lab that Activin A induces subpallial progenitor identity in hPSC-
derived forebrain progenitors, which will be described further in later sections (Cambray et al., 2012; 
Arber et al., 2015).  
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Ligands Type I Rs Type II Rs Smads 
TGFβ ALK5 (TβR-I) TβR-II Smad2/3 
Activin ALK4 ActR-IIB Smad2/3 
Nodal ALK4/7 ActR-IIB Smad2/3 
BMPs ALK2/3/6 BMPR-II/B Smad1/5/8 
Table 1.1: Summary of TGFB superfamily of ligands, their Type I and II receptors (Rs) and associated Smads. 
 
1.2.3 Forebrain development 
After neurulation, morphogen gradients act antagonistically to pattern the forebrain into distinct 
regions of the dorsal pallium and the ventral subpallium, which form the cortex and ganglionic 
eminences respectively. The LGE gives rise primarily to striatal MSNs and olfactory bulb interneurons. 
Cortical and striatal interneurons, as well as globus pallidus projection neurons and basal forebrain 
cholinergic neurons, are born in the MGE (Figure 1.3). The caudal ganglionic eminence (CGE) is thought 
to produce most calretinin interneurons of the striatum and cortex (Pauly et al., 2013; Pilz et al., 2013). 
Division of the forebrain is coincident with the induction of specific transcription factors (Figure 1.3). 
Pallial expression of PAX6 and subpallial expression of GSX2 and DLX1/2 define the pallial-subpallial 
boundary between the dorsal LGE and developing cortex. Although PAX6 expression is much higher in 
the pallium, it is still present in the human LGE. Other transcription factors such as GSX2, DLX1/2, 
ASCL1 (aka MASH1) and OLIG2 are expressed across the whole GE ventricular and subventricular zones 
(VZ/SVZ) (Hansen et al., 2013; Pauly et al., 2013; Onorati et al., 2014). Shh initiates and maintains 
ventral expression of Nkx2.1 in the MGE, which gives rise to cortical and striatal interneurons (Gulacsi 
and Anderson, 2006). In the mouse striatum, Nkx2.1 is restricted to MGE-derived interneurons, and 
the same has been widely assumed and demonstrated in human foetal brain sections (Marin, 
Anderson and Rubenstein, 2000; Nóbrega-Pereira et al., 2008; Hansen et al., 2013; Pauly et al., 2013; 
Wang et al., 2014). Nonetheless, Onorati et al. recently showed that NKX2.1 mRNA and protein is 
present in the 10-11 weeks-post-fertilisation human LGE, albeit at far lower levels than in the MGE. 
They reported that 74% of striatal cells at this stage were NKX2.1-positive with 96% co-expressing 
CTIP2 (aka BCL11B), a MSN marker. By 20 weeks, only 6% of cells in the human foetal striatum 
expressed NKX2.1 (Onorati et al., 2014). It is possible that the low level of NKX2.1 coupled with the 
short time window of expression in the developing striatum have led to the assertion that it is never 
expressed in developing human MSNs. 
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1.2.4 Development of the striatum 
GSX2 is heavily involved in the maintenance of LGE progenitor fate specification by repressing PAX6 
expression, allowing the expression of key ventral transcription factors. In Gsx2 knockout mice, there 
is a delay and reduction in the level of Dlx2 and Ascl1 expression in the LGE, leading to a significant 
reduction in striatal volume, but not a complete abolishment (Szucsik et al., 1997; Toresson, Potter 
and Campbell, 2000). Dlx1 and Dlx2 expression patterns are indistinguishable in the subpallium, and 
they are vital for the differentiation of the later-born matrix MSNs, which develop abnormally in 
double homozygous mutants (Anderson et al., 1997). Indeed, Gsx2 and Dlx1/2 function upstream of 
other key transcription factors such as Helios and Nolz1. Helios is expressed at low levels first in mouse 
LGE progenitors in the SVZ, and then in the developing striatum by new matrix neurons until 
adolescence, when it co-localises with other MSN markers such as Ctip2 and Foxp1. Helios expression 
was completely abolished in both Gsx2 and Dlx1/2 knockout mice, whereas it was unchanged by Ascl1 
mutation (Martín-Ibáñez et al., 2012). Nolz1 is expressed mostly in SVZ LGE progenitors and appears 
to have a role in promoting cell cycle exit and neuronal differentiation via Gsx2-dependent 
upregulation of retinoic acid (RA) signalling (Jensen, Björklund and Parmar, 2004; Urbán et al., 2010). 
RA is released by local glia in the LGE and plays an important role in promoting the GABAergic 
Figure 1.3: Schematic diagram of a coronal section through the developing telencephalon. 
Cells are patterned by ventral SHH and dorsal Gli3R, which antagonise one another. Cells born in the MGE 
migrate to the globus pallidus, striatum and cortex, and express different subtype markers, while LGE-born MSNs 
populate the adjacent striatum (left). The LGE (red) and MGE (blue) have distinct expression patterns of 
molecular markers, but also share expression of pan-GE transcription factors (purple). LGE progenitors mature 
into striatal MSNs with their own combination of markers (orange; right). INs = interneurons. 
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phenotype of both striatal MSNs and interneurons (Toresson et al., 1999; Chatzi, Brade and Duester, 
2011). 
 By E14 in the rat and 50 days post fertilisation in the human foetus, juvenile post-mitotic neurons in 
the mantle zone of the LGE and striatal anlage cease to express GSX2 and DLX2 and are identified 
instead by the presence of CTIP2, FOXP1 and FOXP2 (Martín-Ibáñez et al., 2012; Pauly et al., 2013). 
Mature MSNs can be identified by their expression of DARPP32 in combination with the 
aforementioned transcription factors. Co-expression of these proteins is necessary to reliably identify 
cells as MSNs, as each of them is individually expressed in cortical cells (Onorati et al., 2014). CTIP2 is 
a transcription factor that is crucial in the development of the neocortex, hippocampus and olfactory 
bulb; but within the striatum it is exclusively expressed in MSNs, showing complete co-expression with 
DARPP32 and FOXP1 (Arlotta et al., 2008; Onorati et al., 2014). Ctip2 knockout mice appear to have 
normal birth of MSNs in the LGE followed by migration to the striatum, however at E15.5 they begin 
to show reduced striatal Foxp1 expression and disorganised striatal compartments. Specifically, MSNs 
fail to arrange themselves into striosomes and many MSN markers, particularly those of the direct 
pathway MSNs found in striosomes, show dramatically reduced expression, including DARPP32. 
Furthermore, aberrant striosome formation appears to be responsible for abnormal dopaminergic 
innervation that is usually richest on striosome MSNs (Arlotta et al., 2008). The lack of changes in the 
LGE progenitor population in Ctip2 knockout mice shows that it is more likely to play a role in post-
mitotic maturation and connectivity of MSNs, as it does in corticospinal motor neurons (Arlotta et al., 
2005). Genome-wide ChIP-sequencing of an immortalised mouse striatal cell line over-expressing 
Ctip2 further showed a role in BDNF signalling, which is also vital for DARPP32 expression in mouse 
MSNs (Ivkovic and Ehrlich, 1999; Tang et al., 2011). Most notably, CTIP2 mRNA and protein was found 
to be significantly decreased in both the R6/1 HD mouse model and human HD patient brains 
(Desplats, Lambert and Thomas, 2008). Overexpression of Ctip2 also diminished the toxic effects of 
mutant HTT on cultured neurons, supporting an important role for CTIP2 in the specific vulnerability 
of MSNs in HD. 
Striatal interneurons born in the MGE and CGE must migrate to the striatum, which happens around 
E15 in mouse. High Nkx2.1 expression is the main distinguishing feature of the MGE, and mice lacking 
Nkx2.1 develop MGEs that resemble LGE and fail to produce almost any striatal interneurons (Marin, 
Anderson and Rubenstein, 2000). Nkx2.1 expression is driven and maintained by Shh signalling, which 
not only arises from the ventro-dorsal Shh gradient across the telencephalon, but is also determined 
by an internal gradient of Shh signalling that is higher in the dorsal MGE than in the ventral region (Xu 
et al., 2010). In this study, mosaic loss of Shh signalling by Smo knockdown led to Nkx2.1 
downregulation and Gsx2 upregulation in the cells lacking Smo, producing bipolar CR interneurons 
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reminiscent of those born in the CGE, where Gsx2 expression is also high. Interestingly, this also caused 
neighbouring cells expressing Smo to upregulate Shh pathway genes resulting in a higher number of 
SST than PV interneurons. This was in agreement with a previous study showing that SST interneurons 
arise from the dorsal MGE while PV interneurons develop from more ventral progenitor pools (Flames 
et al., 2007). In addition, the ventral-most region of the MGE appears not to produce any GABAergic 
interneurons, but instead gives rise to globus pallidus projection neurons and cholinergic neurons of 
the basal forebrain and striatum (Flandin, Kimura and Rubenstein, 2010). 
The mechanism that defines whether MGE-derived interneurons migrate to the striatum or the cortex 
remains unclear, but the result is that the two populations have distinct responses to migratory cues 
by expression of specific membrane receptors. Marin et al. first demonstrated that expression of 
semaphorins in the striatum repelled migrating cortical interneurons that expressed neuropilins 1 and 
2, and that loss of neuropilin expression led to increased striatal interneurons (Marin et al., 2001). The 
same group later showed that Nkx2.1 downregulation in cortical interneurons was the key step in 
allowing neuropilin expression and repulsion from the striatum (Nóbrega-Pereira et al., 2008). By 
forcing expression of Nkx2.1 they were able to increase the number of interneurons in the striatum, 
while preventing post-mitotic Nkx2.1 expression led to a reduction in striatal interneurons. This 
mechanism was further elucidated to show that Zfhx1b expression is required downstream of Dlx1/2 
to repress Nkx2.1 and allow interneuron migration to the cortex (McKinsey et al., 2013). The majority 
of past research on this subject has been aimed at finding the mechanisms behind interneuron 
migration to the cortex. A recent study by the Marin group focussed on what causes interneurons to 
settle in the striatum (Villar-Cerviño et al., 2015). They found that, in a similar way to cortical 
interneurons, striatal interneurons are both attracted to the striatum through ErbB4/Nrg-1 
interactions and simultaneously repelled by the cortex via Eph/ephrin signalling. The EphB expression 
is therefore likely to be downstream of maintained Nkx2.1 expression. Also downstream of Nkx2.1 are 
Lhx6 and Lhx8, expressed by post-mitotic GABAergic and cholinergic interneurons respectively, in both 
the cortex and striatum (Marin, Anderson and Rubenstein, 2000; Hansen et al., 2013). These studies 
highlight the limited knowledge we still have of the processes behind striatal development, and 
considering the differences between rodent and human striatal cell composition, more studies must 
be done in human tissue in order to confirm the relevance of these findings. 
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1.3 Human pluripotent stem cells 
Human embryonic stem cells (hESCs) are derived from the inner cell mass of a human embryo and 
have the unique ability to self-renew and maintain their pluripotency in culture, given the correct 
extrinsic signals (Thomson et al., 1998). A similar type of pluripotent stem cell was discovered by 
Takahashi et al., whereby they induced pluripotency (iPSCs) in adult human fibroblasts by viral 
transduction of four key transcription factors: OCT3/4, SOX2, KLF4 and c-Myc (Takahashi et al., 2007). 
Together, hESCs and hiPSCs can be termed human pluripotent stem cells (hPSCs), where pluripotency 
is defined as both the ability to self-renew and have the potential to differentiate into any cell type in 
the body. Maintaining cells in the pluripotent state has evolved from requiring feeder layers of mouse 
embryonic fibroblasts secreting unknown factors, to now widely used fully defined media and matrices 
on which to grow hPSCs (Ludwig et al., 2006). 
Known developmental principles can be applied to hPSCs to pattern them towards a particular cell 
fate, making them an excellent tool to study unknown developmental pathways as well as to obtain 
limitless supplies of specific cell types of interest. Human PSC-derived neurons allow access to live 
human neurons that could only previously be achieved through obtaining human foetal tissue, which 
cannot be quality-controlled or standardised. The motivation for generating particular cell types 
comes, inevitably, largely from those affected in disease. For example, there is a strong interest in 
generating midbrain dopaminergic neurons for cell replacement therapy for PD, and GABAergic 
interneurons for epilepsy (Kriks et al., 2011; Kirkeby et al., 2012; Maroof et al., 2013; Cunningham et 
al., 2014). This thesis is focused on producing striatal MSNs and interneurons for cell therapy in 
Huntington’s disease. Nonetheless, the value of hPSCs extends far beyond regenerative medicine to 
the potential to study the development of live human neurons in vitro, as well as compare healthy 
development and neuronal function with neurons derived from patient iPSCs or hESC lines with 
targeted gene mutations. This will provide a useful platform for high throughput screening of potential 
therapies before taking them into animal models. 
1.3.1 hPSCs as a model of embryonic development 
Pluripotent stem cells are an ideal tool for modelling development and defining the mechanisms of 
pluripotency and differentiation. A pioneering study demonstrated that inhibition of TGFβ and BMP 
signalling lead to neural induction of hESCs in fully defined monolayer conditions, by inhibiting 
induction of mesoderm or endoderm (Chambers et al., 2009). They provided an easily manipulable 
tool on which to test different conditions for promoting differentiation of human cells. Over time, it 
has been confirmed that many of the known signalling events in the developing nervous system can 
be applied to hESCs to achieve expected gene expression profiles. However, this is generally limited 
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to broad morphogen gradients across the developing brain. The flexibility of hESCs allows the 
researcher to make fine adjustments in factor concentration and treatment time windows to optimise 
the induction of one particular developmental region. For example, varying the concentration of SHH 
to mimic different dorso-ventral positions and obtain more LGE or MGE-like cells (Li et al., 2009). 
Similarly, altering SHH application time windows changes their rostro-caudal position to produce more 
MGE or hypothalamic cells (Maroof et al., 2013). Conversely, novel putative developmental pathways 
can be discovered that were not previously known, such as the ability of Activin to induce LGE or CGE 
fate (Cambray et al., 2012; Arber et al., 2015). Finally, once differentiation protocols are reliably 
established, the role of specific proteins can be probed by targeted genetic mutations. The relatively 
novel CRISPR-Cas9 technology allows high efficiency and precise gene editing, including insertion or 
deletion of specific gene sequences (Kearns et al., 2014). This can be applied in a similar way to mouse 
genetic manipulation studies, to look at the effects of knocking out or over-expressing specific genes 
on the differentiation of specific cell types. 
1.3.2 hPSCs for disease modelling and drug screening 
The discovery of human iPSCs has opened up a whole new opportunity of in vitro disease modelling 
that allows the production of neurons from patient-derived cells, whose disease symptoms can be 
profiled and matched to any in vitro phenotypes observed (Takahashi et al., 2007). While this is useful 
for monogenic diseases such as HD, as it avoids the need for editing a hESC line, it is particularly 
valuable to the study of polygenic diseases with multiple risk factors, such as schizophrenia and autism 
spectrum disorder (ASD) (Brennand et al., 2011). Further to their applications in developmental 
biology, patient iPSCs can be compared to healthy PSCs to observe differences in the way the cells 
differentiate and mature into neurons. The generation of iPSCs from patient fibroblasts enables the 
expansion of a limited number of cells into an unlimited cell line that can be used for large scale studies 
and high throughput screening of potential therapies. One limitation to these studies currently is 
choosing the phenotypes to study, especially in psychiatric disorders where knowledge of disease 
mechanisms at the cellular level are extremely limited. Because HD is a monogenic disease, decades 
of in vivo and in vitro model research have highlighted the key pathways involved in the disease. On 
this basis, studies have already managed to show some impairments in cell metabolism, adhesion and 
death using HD iPSC-derived neurons (Zhang et al., 2010; The HD iPSC Consortium, 2012). Enrichment 
of striatal cell types in these studies would greatly improve their relevance to the disease. 
1.3.3 hPSCs for regenerative medicine 
Cell replacement therapy relies on the possibility that cells can be implanted into a specific part of the 
body and adopt the identity and function of the damaged cell population such that they can partly or 
fully restore the tissue. Clinical trials using human foetal tissue to replace lost neurons in PD and HD 
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have shown that the procedure can be safe and produce positive functional benefits to patients 
(Wenning et al., 1997; Hagell et al., 1999; Bachoud-Lévi et al., 2006). Difficulties with reproducing 
consistently successful outcomes in these trials has brought into question whether clinical trials should 
be open-label or double-blind placebo controlled, however it is also likely that the variation between 
foetal grafts also plays a large role (Evans, Mason and Barker, 2012). Another huge obstacle in the 
routine clinical use of foetal tissue is that it is in very limited and declining supply. Human PSCs 
represent the most suitable source of cells for progression in this field, as they can be thoroughly 
quality controlled and produce an unlimited supply of tissue for transplantation. 
Preclinical studies in PD models have provided very promising results both of histological and 
functional integration of the hPSC-derived grafts in rodent and non-human primate models (Kriks et 
al., 2011; Grealish et al., 2014; Hallett et al., 2015). These cells are likely to enter into clinical trials in 
the near future. 
Researchers at the Jules Stein Eye Institute recently published their findings from a Phase I clinical trial 
using hESC-derived retinal pigmented epithelial cells (Schwartz et al., 2012). The treatment caused no 
adverse effects and appeared safe 4 months post-transplantation, and there were even some 
improvements in vision measured in both patients. This is the first clinical trial using either iPSCs or 
hESCs as the source of cells for transplantation, but other trials are in the pipeline (Carr et al., 2013).  
Much research is now focused on devising protocols for robust generation of specific cell types from 
hPSCs for this purpose. 
1.3.4 Neural differentiation of hPSCs 
There are several methods by which an enriched population of neurons can be derived from hPSCs. 
Embryoid bodies (EBs) are formed when hPSCs are grown in suspension in the absence of feeder cells 
or pluripotency-inducing growth factors. These EBs go through the normal steps of embryonic 
development, and therefore form the three germ layers – endoderm, mesoderm and ectoderm. Zhang 
et al. demonstrated that exposure of plated EBs to FGF2 was sufficient to promote self-organisation 
into neural rosettes and neural precursor proliferation (Zhang et al., 2001). Enzymatic isolation of the 
neural rosettes yielded 96% neural cells, which were subsequently expanded in suspension and then 
plated in the absence of FGF2 to initiate terminal differentiation. This is a method that is still widely 
used, and indeed has been applied to the production of ventral telencephalic neurons by adding 
recombinant SHH and Wnt inhibiting molecules (Li et al., 2009; Danjo et al., 2011). The EB method 
produces a high yield of neurons and large scale bioreactor culture systems make it easily applied to 
high throughput screening studies. However, cells within the EB are exposed to different levels of 
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patterning factors and inevitably produce their own unknown signalling molecules making it difficult 
to achieve defined and homogeneous cultures enriched for a single neuronal subtype. 
Organoids are in vitro-derived tissues that exploit the huge capacity of either tissue stem cells or PSCs 
to self-organise by embedding EBs into a matrix to support their growth into much larger structures. 
This was first shown using intestinal stem cells to produce tissues containing crypts and villi, including 
all the relevant cell types (Sato et al., 2009). More recently, this was applied to developing cortex-like 
tissues, complete with ventricular zone and layer-specific marker expression (Lancaster et al., 2013). 
This type of research compromises on homogeneity for system complexity, and models well the early 
developmental processes in the human cortex, but will not be applicable for generating specific 
neuronal cell types. 
Several mouse stromal cell lines are able to induce neural differentiation when co-cultured with hPSCs, 
however the mechanism by which this occurs remains unknown (Perrier et al., 2004). Stromal co-
cultures can induce 30-50% neurons from hPSCs, and was the method behind the first MSN 
differentiation protocol (Aubry et al., 2008). Nonetheless, its use of animal feeder cells prevents any 
clinical applications and makes more defined methods more attractive for research purposes. 
A defined monolayer differentiation method for neural induction of hPSCs was first described by 
Chambers et al., in which the organising effects of the TGFβ-family inhibitors chordin, follistatin and 
noggin were reproduced in vitro (Chambers et al., 2009). “Dual-Smad inhibition” of hPSCs first used 
recombinant noggin with the small molecule SB431542 (ALK4/5 inhibitor) to efficiently generate a 
population of forebrain progenitors responsive to additional patterning cues. A later study found that 
LDN193189 effectively mimics the BMP inhibition induced by noggin (Boergermann et al., 2010). The 
default fate for hPSCs is of dorsal forebrain identity, but many differentiation protocols have already 
been devised to generate various other neuronal subtypes including midbrain dopaminergic neurons 
(Jaeger et al., 2011; Kriks et al., 2011; Kirkeby et al., 2012), cortical interneurons (Cambray et al., 2012; 
Maroof et al., 2013) and striatal MSNs (Carri et al., 2013; Nicoleau et al., 2013; Arber et al., 2015). The 
monolayer differentiation method exposes cells uniformly to fully defined culture medium containing 
specific patterning factors. Cells therefore differentiate in a much more synchronous and 
homogeneous manner to other methods making it the ideal choice for producing specific neuronal 
cell types for in vitro modelling or for cell therapy. 
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1.3.5 Directed differentiation of hPSCs towards striatal neurons 
1.3.5.1 Generation of MSNs from hPSCs 
Research that laid the foundation for MSN-specific differentiation protocols found that precise 
concentrations and timing of SHH with or without Wnt inhibition were able to pattern hESC-derived 
telencephalic progenitors towards LGE or MGE lineage (Aubry et al., 2008; Li et al., 2009). The first 
group to  publish a method specifically for MSN differentiation used mouse stromal cell co-culture for 
neural induction of hESCs (Aubry et al., 2008). Isolated neural rosettes were treated with BDNF to 
anteriorise, and SHH (200 ng/ml) and DKK1 (100 ng/ml) to ventralise the cells. Neural induction with 
this method was fairly inefficient, with only 22% of cells expressing the neuronal marker MAP2. 
However, more than half of the neurons were DARPP32-positive, suggesting that SHH and DKK1 are 
at least somewhat effective in patterning hESCs towards MSN fate. They tested the in vivo potential 
of the cells at different stages of in vitro differentiation. Early stage cells produced teratoma-like 
regions of non-neuroectodermal identity, or neural rosette structures at best, while transplantation 
of mature neurons caused very poor graft survival. The stage at which cells could be characterised as 
LGE progenitors, expressing nestin, GSX2 and DLX2, was the best stage for graft survival, DARPP32 
expression and lack of teratoma formation. When grafted into QA-lesioned nude rats and left for up 
to 21 weeks, all animals developed overgrown grafts that compressed the host brain considerably. 
DARPP32-positive regions were seen throughout the grafts, but the vast majority of cells were still 
dividing despite neural lineage commitment. 
The ventralising effect of SHH was further explored by Ma et al., who used the embryoid body method 
to generate neuroepithelial cells that were then manually isolated and re-plated (Ma et al., 2012). 
Cells were treated with SHH (200 ng/ml) at a dose they found to be most effective at down-regulating 
PAX6 and up-regulating ASCL1, MEIS2 and GSX2, while keeping NKX2.1 expression to a minimum of 
30%. Neural induction was far more efficient than in the study by Aubry et al., with 93% of cells 
expressing βIII-tubulin. Of the neurons, 80% were double-positive for DARPP32 and GABA. Whole cell 
patch clamping demonstrated the cells’ ability to generate action potentials during current steps, and 
blockade of spontaneous synaptic activity using bicuculline, a GABA receptor inhibitor. Transplanted 
LGE-like progenitors in the QA-lesioned striatum of SCID mice, reportedly produced around 60% 
GABAergic neurons, the majority of which were DARPP32-positive. There was host innervation of the 
graft by TH and VGLUT expressing fibres, suggesting integration into the host brain. Animals showed 
significant functional recovery in rotarod, open field and treadscan testing compared to lesion only 
animals. While this study demonstrated high efficiency in generating functional DARPP32-positive 
MSNs, the manual isolation of neural colonies step is crucial for getting rid of unwanted cell types, 
making this protocol unsuitable for large scale systematic use. 
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Both Carri et al. and Nicoleau et al. demonstrated the efficacy of monolayer neural induction (51 and 
58% MAP2-expressing cells respectively), and built upon the previous findings of the latter group 
(Aubry et al., 2008; Carri et al., 2013; Nicoleau et al., 2013). Carri et al. added SHH (200 ng/ml) and 
DKK1 (100 ng/ml) from day 5 for 3 weeks to ventralise the cells, resulting in 52% CTIP2/GABA-positive 
neurons and 20% DARPP32-positive neurons (Carri et al., 2013). These neurons exhibited MSN-like 
electrophysiological characteristics of an onset delay in firing the first action potential as well as 
inhibitory post-synaptic currents indicative of GABAergic signalling. Upon transplantation into QA-
lesioned rat striatum, DARPP32-expression was observed at 9 weeks, but massive graft overgrowth 
meant this was a very small number of cells. There was a significant reduction in apomorphine-induced 
rotations in the grafted group at 3 and 6 weeks in the absence of mature MSNs, but not at 9 weeks, 
suggesting this may have been a transient neurotrophic effect of the immature graft rather than due 
to functional integration. Nicoleau et al. optimised their previous factor concentrations, 
demonstrating that inhibition of Wnt signalling by DKK1 or the small molecule inhibitor, XAV-939, 
enhanced forebrain patterning of the cells in a dose-dependent manner (Nicoleau et al., 2013). In 
addition, they showed that a lower concentration of SHH (50 ng/ml) was more effective in generating 
LGE progenitors, while the higher concentration they used previously resulted in 80% of cells 
expressing NKX2.1, a MGE marker. Together, SHH (50 ng/ml) and XAV-939 (1 uM) generated 28% 
DARPP32-positive neurons, producing both a higher proportion of neurons and MSNs than Carri et al.. 
They also presented evidence of the two MSN subpopulations expressing DRD1 or DRD2 that form the 
direct and indirect basal ganglia pathways respectively. Transplantation of the LGE progenitors 
produced large grafts that contained extensive FOXG1, CTIP2, FOXP1, and DARPP32 expression 
throughout and innervation by host TH fibres. These protocols demonstrate the ability to produce 
relatively high proportions of MSNs from hESCs using monolayer differentiation, but also emphasise 
the need for protocols that produce transplantable cells that will not overgrow in vivo. 
Our lab has taken a completely novel approach to generating MSNs from hPSCs, by exploiting Activin 
A (hereafter named Activin) signalling to induce LGE and MSN fate (Arber et al., 2015). Prior to 
discovering its effects on MSN differentiation, former lab members had found that Activin could 
induce a CGE-derived calretinin interneuron fate (Cambray et al., 2012). The CGE is often described as 
a caudal extension of the LGE, and has a highly overlapping transcription factor expression profile 
including GSX2 and DLX2. Evidence for TGFβ family signalling in the developing subpallium, specifically 
the presence of Activin subunits, receptors and phosphorylated Smad2, support the concept of a 
patterning role for Activin in the ventral forebrain (Feijen, Goumans and van den Eijnden-van Raaij, 
1994; Maira et al., 2010). By testing different timing and concentrations of Activin, it was found that 
an earlier and higher dose of Activin increased pan-GE markers GSX2 and DLX2, but had no effect on 
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the MGE markers NKX2.1 and LHX8 (Arber et al., 2015). Furthermore, Activin stimulated a large 
increase in CTIP2 expression after just 12 hours, hinting that it may have a direct regulatory effect on 
its expression. LGE progenitors at around day 20 of differentiation expressed GSX2, DLX2, CTIP2, 
FOXP2 and NOLZ1. This protocol has now been applied to multiple hESC and hiPSC lines by several 
researchers, consistently generating 20-40% DARPP32-positive neurons, with around 80% of cells 
NeuN-positive. At day 20, LGE progenitors were transplanted into QA-lesioned rat striatum (given 
immunosuppressant) and analysed 4, 8 and 16 weeks after. DARPP32 staining was visible by 8 weeks, 
and at 16 weeks 50% of graft cells were DARPP32-positive. FOXP2, calbindin, GABA, substance P and 
enkephalin were also expressed throughout the grafts at 16 weeks. Host TH fibres appeared to 
innervate the grafts, and human NCAM-positive fibres were observed extending out of the graft core 
towards the globus pallidus and midbrain. There was no Ki67 staining at 16 weeks, and no indication 
of graft overgrowth, however the grafts were actually very small and no improvement was seen in 
apomorphine-induced rotations. Activin induction of MSN fate in hPSCs is arguably the most efficient 
monolayer differentiation method for producing MSNs, and appears to have an advantage in not 
promoting overgrowth in vivo. However, because very little is known about Activin signalling in striatal 
development, more research must be done to decipher the mechanism by which Activin exerts its 
patterning effects in vitro. 
1.3.5.2 Generation of striatal interneurons from hPSCs 
Striatal interneurons originate from the MGE and CGE and fall into several subtypes defined by their 
expression of distinct markers (Figure 1.3). GABAergic CR interneurons that derive from the CGE can 
be generated by treating late born hPSC-derived forebrain progenitors with Activin (Cambray et al., 
2012). All other interneuron subtypes are born in the MGE, a single developmental structure that gives 
rise to many cell types, making enrichment of one cell type over another more challenging. Cortical 
GABAergic interneurons expressing PV or SST are of most interest in current research, due to their 
emerging role in autism, schizophrenia and epilepsy (Liu et al., 2013; Maroof et al., 2013; Cunningham 
et al., 2014). However, striatal cholinergic interneurons and basal forebrain cholinergic neurons have 
also been highlighted as cell types of interest for modelling dystonia and Alzheimer’s disease 
respectively in vitro (Crompton et al., 2013; Capetian et al., 2014). Striatal GABAergic interneurons are 
becoming increasingly implicated in HD and their potential importance in a functioning striatal graft 
for HD cell therapy has also been recently emphasised (Reiner et al., 2013; Reddington, Rosser and 
Dunnett, 2014). Fortunately, efforts to generate cortical interneurons from hPSCs have resulted in the 
production of all the above cell types. In theory, distinguishing between cortical and striatal 
interneurons is possible by looking at co-expression of NKX2.1 and LHX6 in striatal interneurons, 
however this involves some practical challenges, not least finding reliable antibodies that can be used 
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in combination (Nóbrega-Pereira et al., 2008). All protocols for generating cortical interneurons have 
used a combination of Wnt inhibition followed by SHH activation, due to the strong NKX2.1-inducing 
effect of high SHH concentrations that pattern the MGE in vivo. 
The embryoid body neural induction method was used by Li et al., who applied different 
concentrations of SHH with or without DKK1 to hESC-derived neuroepithelial cells (Li et al., 2009). 
They found that the higher dose of SHH (500 ng/ml) induced NKX2.1 expression in 84% of cells, 94% 
of which were FOXG1-positive indicating their ventral forebrain identity. Addition of DKK1 reduced 
the proportion of PAX6-positive cells and increased NKX2.1 mRNA levels. After further maturation of 
the cells, many stained positive for GAD67, and a few cells were also CTIP2/DARPP32-positive, showing 
some LGE induction as well as MGE. However, in this study they did not look at whether there was 
expression of any interneuron subtype markers. 
Following this study, there was a relatively long period of silence in the field of hPSC-derived 
interneurons, which came to an end in May 2013 with the publication of three new papers in one 
month, plus another two soon after (Germain et al., 2013; Liu et al., 2013; Maroof et al., 2013; Nicholas 
et al., 2013; Kim et al., 2014). Liu et al. used only a high dose of SHH (1000 ng/ml) to pattern hESCs 
towards MGE progenitors, and no Wnt inhibition. They obtained 38% and 45% of cholinergic and 
GABAergic neurons respectively. When transplanted into the hippocampus of a lesioned mouse model 
of learning and memory impairment they generated 8% and 45% ChAT and GABA-positive cells 
respectively and caused improvement in the learning and memory deficits (Liu et al., 2013). In 
contrast, Kim et al. used a small molecule-based approach with IWP-2, a Wnt inhibitor, and SAG, a 
SHH activator (Smo agonist), from day 0. They are also the only group that applied FGF8 to the ventral 
forebrain progenitors in order to eliminate COUP-TFII expression, a CGE marker, and increase NKX2.1 
expression to 80%. They also observed around 1% of cells expressing PV or SST, and in another 
publication showed that the cells could suppress seizures and improve behavioural impairments in 
epileptic mice (Cunningham et al., 2014; Kim et al., 2014). 
Nicholas et al. used a NKX2.1/GFP reporter hESC line to facilitate their study. They applied DKK1 and 
another SHH activator, Purmorphamine, to EBs from day 9, producing 75% NKX2.1-positive cells, 81% 
of which co-expressed FOXG1. They followed the maturation of the cells in vitro for 30 weeks, and 
showed that hPSC-derived neurons develop along a similar timeline to human development, 
dramatically improving in functional maturation by the last time point. Despite the identification of 
10% PV-positive cells at 15 weeks, this had reduced to just 1.5% by 30 weeks, with 40% SST and 77% 
calretinin. A population of NKX2.1/LHX6 double-positive cells indicated the presence of both striatal 
and cortical interneurons in their cultures (Nicholas et al., 2013). 
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Finally, Maroof et al. used a monolayer differentiation to test different time windows of SHH 
treatment to optimise NKX2.1-positive cells that were MGE-like rather than the more caudal pre-optic 
area or hypothalamus, which also express NKX2.1. Also using a NKX2.1/GFP reporter hESC line, they 
looked at co-expression with OLIG2 and FOXG1 to determine the condition that produced the most 
MGE-like progenitors. Unlike many of the other groups, they demonstrated that beginning SHH 
treatment early (day 2-18) lead to the generation of hypothalamic-like progenitors. Intermediate SHH 
treatment (day 6-18) favoured the generation of cholinergic (50%) over GABAergic (15%) 
interneurons, while later addition of SHH produced 70% GABAergic and just 5% cholinergic 
interneurons. Other optimisation experiments found that supplementation of 5nM SHH treatment 
with 1 µM Purmorphamine was able to optimally induce NKX2.1 and reduce the use of expensive 
recombinant SHH. PV and SST were each expressed by 40% of NKX2.1-positive cells, and no calretinin-
expressing cells were detected. NKX2.1-positive progenitors were transplanted into mouse cortex, but 
after 2 months cells remained immature and had not differentiated into neuronal subtypes (Maroof 
et al., 2013). This last protocol appears to be the most effective at generating MGE-like GABAergic 
interneurons, but their in vivo potential requires further assessment to see if they can mature over a 
longer time scale. 
These studies have demonstrated that it is relatively easy to generate a high proportion of NKX2.1-
positive MGE-like progenitors, but that their maturation into specific subtypes is very slow and 
requires more research. It appears that both cortical and striatal interneurons can form from these 
hPSC-derived MGE progenitors, but this remains to be confirmed with in vivo experiments. 
1.3.6 Direct reprogramming of somatic cells into striatal neurons 
Induced neuron (iN) technology involves direct reprogramming of post-mitotic somatic cells into 
mature neurons by forcing expression of lineage-specific transcription factors (Vierbuchen et al., 
2010). Direct conversion of human adult fibroblasts to MSNs was performed by viral transduction of 
brain-enriched micro-RNAs, miR-9/9* and miR-124, together with a combination of MSN-specific 
transcription factors (Victor et al., 2014). While the micro-RNAs efficiently induced neuronal markers, 
CTIP2 was the only transcription factor tested (of 16) that was able to induce DARPP32 expression. 
DLX1 and DLX2 were found to increase the proportion of GABAergic neurons, and MYT1L improved 
the yield of MAP2-positive cells. With immunostaining on cells 5 weeks post-transduction they found 
that 82% were neurons, and 77% of neurons were DARPP32-positive MSNs. When cells were 
transplanted into mouse striatum after reprogramming, 91% of cells became DARPP32-positive, and 
their functional properties very closely resembled those of the native mouse MSNs. 
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GABAergic interneurons have also been generated using iN technology, this time without the use of 
micro-RNAs for efficient neuronal conversion (Colasante et al., 2015). ASCL1 has also been shown to 
induce a high proportion of neurons with this method, so they tested other MGE-specific transcription 
factors in combination with ASCL1, using a GAD67-GFP mouse embryonic fibroblast line (Vierbuchen 
et al., 2010). Colasante et al. found that FOXG1, SOX2, LHX6 and DLX5 increased the GABAergic 
population of neurons in an additive way, achieving GFP/GAD67 expression in 15% of plated 
fibroblasts. More than 90% of the GABAergic neurons were PV-positive, while a very low proportion 
expressed SST. Repeating this experiment using human iPSCs, more than half of neurons were 
GABAergic while 90% of neurons were PV-positive, raising the question as to why the other 40% of 
PV-positive neurons were not GABAergic. They assessed the efficiency of the conversion and 
estimated it at more than 30%, better than with the mouse cells. A third of cells displayed repetitive 
action potential firing upon current injection, but this was at a much lower frequency than observed 
in real PV interneurons. 
These two studies demonstrate a novel way of studying the genes involved in fate commitment of 
specific cell types. For example, the iN-MSN study further confirmed the importance of CTIP2 in MSN 
development, which had already been suggested in knockout studies and our own research into MSN 
differentiation from hPSCs (Arlotta et al., 2008; Victor et al., 2014; Arber et al., 2015). It is also a fast 
and relatively efficient way of generating a small number of mature human neurons from somatic 
cells, which may be useful for specific tests on skin biopsies. However, such tissue samples are limited 
in scale and there is no opportunity of expansion of these post-mitotic cells, making them unsuitable 
for standardised drug screening or regenerative medicine. 
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1.4 Aims 
Efficient in vitro generation of functional striatal neurons is crucial for the progress of regenerative 
medicine as well as modelling healthy and diseased striatal development in vitro. 
The aims of this project are to investigate the mechanisms by which Activin induces an MSN fate in 
hPSC-derived forebrain progenitors by manipulating the exogenous factors to which they are exposed 
and measuring intracellular changes, such as protein or gene expression. This will both provide new 
information on the processes involved in human MSN differentiation and could lead to the discovery 
of other pathways that further enrich MSN generation. 
The second aim is to assess whether current cortical interneuron differentiation protocols can be 
applied for the generation of striatal interneurons, both in vitro and in vivo. This involves 
characterising how these interneurons survive, migrate and differentiate following transplantation 
into neonatal rat brain. 
Together, hPSC-derived striatal MSNs and interneurons will provide a valuable tool for the 
aforementioned applications.  
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2 Methods and materials 
2.1 Cell culture 
All cell cultures were maintained at 37°C and 5% CO2 (Galaxy 170 R, New Brunswick). Cell work was 
carried out under a laminar flow hood (Maxisafe 2020, Thermo Scientific) under sterile conditions. 
Cells were grown on cell culture-treated plastic multi-well plates (Thermo Scientific) or glass coverslips 
(VWR).  
2.1.1 hPSC culture 
All experiments were carried out using H7 hESC line or their tau-GFP-transfected counterparts (TG-
H7) unless otherwise stated (2.1.2). Multi-well plates were coated with hESC-qualified Matrigel 
(Corning) diluted in DMEM/F-12 (Gibco) for at least 1 hour at 37°C. H7 were maintained in mTeSR1 or 
TeSR-E8 medium and TG-H7 cell lines were maintained in TeSR-E8 medium (Stem Cell Technlogies). 
All media were changed at least every other day and cells were passaged when they reached 80% 
confluency as follows. All media was aspirated and cells were washed with D-PBS (Gibco) once, then 
EDTA 0.02% (Sigma) was added and the cells incubated at 37°C for 1-2 mins. EDTA was aspirated and 
medium added. A serological pipette was used to scratch and manually dissociate the cells by titrating 
into small clusters. Cell suspension was centrifuged at 1150 rpm for 3 minutes (5810 R, Eppendorf) to 
create a cell pellet that was resuspended in fresh medium and seeded at a 1:1, 1:2, and 1:5 ratios. 
2.1.2 hPSC freezing and thawing 
Cells were stored in liquid nitrogen tanks at low passage numbers for future use. Cells were passaged 
as described above (2.1.1) but kept in large clusters and resuspended in medium containing 10% 
DMSO. Cell suspension from one well of 80% confluency was transferred into a cryogenic vial and 
placed inside a cell freezing container to slow the rate of freezing once placed at -80°C. Cells were kept 
at -80°C for up to 1 week before being placed in liquid nitrogen storage tanks. Cell thawing was carried 
out as quickly as possible by placing cryogenic vials straight from liquid nitrogen at 37°C. Thawed cell 
suspension was transferred to pre-warmed medium and centrifuged at 1150 rpm for 3 minutes. The 
cell pellet was resuspended in fresh medium and plated into a single well. 
2.1.3 hESC transfection (with Claudia Tamburini) 
H7 hESCs were transfected with a plasmid containing a CAG-tau-GFP construct to drive constitutive 
expression of a tau-GFP fusion protein, and a puromycin resistance cassette (puromycin 
acetyltransferase) for selection of cells expressing the transgene. Plasmid DNA was prepared for 
transfection by ethanol precipitation as follows. 5 µg DNA was made up to 100 µl with TE buffer, 
sodium acetate (1/10th volume, 3M) was added, the tube was filled with 100% ethanol and placed at 
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-20°C overnight. DNA was centrifuged at 15,000 x g for 15 minutes at 4°C, the pellet was washed with 
70% ethanol and the centrifuge step repeated. The pellet was air-dried under a laminar flow hood and 
resuspended in TE buffer. Two 80% confluent wells of H7 hESCs were pre-treated with ROCK inhibitor 
(10 µM, Y-27632), dissociated with dispase (7 minutes at 37°C) and medium was added to stop the 
reaction. Cells were resuspended in P3 buffer (Lonza) with 2 or 4 µg of plasmid DNA and transferred 
to a cuvette for electroporation with the Lonza 4D-Nucleofector using the CB-150 program. Cells were 
re-plated in medium with ROCK inhibitor. 
Medium was changed 48 hours later with mTeSr1 plus puromycin (1 µg/ml) for selection of cells 
containing the transgene. Following selection, 5 colonies grew large enough for picking, expanding 
and freezing. Of those, 4 clones (TG2, 3, 4 and 5) were stable enough for continuous culture and 
differentiation, but TG2, 3 and 5 switched off the transgene during neural differentiation. TG4 was 
used for all experiments requiring GFP expression. 
2.1.4 hPSC neural differentiation 
Cells were passaged as above (2.1.1) but plated on Growth Factor Reduced Matrigel (diluted 1/15 in 
DMEM-F12 and coated for 1 hour at 37°C; Corning) in mTeSR1 or E8. When cells were >90% confluent, 
medium was changed to N2B27-defined medium: 100 ml DMEM-F12, 50 ml Neurobasal, 1 ml N2 
supplement, 1 ml B27 without retinoic acid, 2 mM L-glutamine, penicillin-streptomycin, 0.1 mM β-
mercaptoethanol (all from Gibco). This was designated as day 0 of differentiation. For MSN 
differentiation, the ALK4/5/7 inhibitor SB431542 (SB; 10 µM; Tocris) was added to medium from day 
0-5. The ALK2/3/6 inhibitors dorsomorphin (200 nM; Tocris) and LDN193189 (LDN; 100 nM; Tocris) 
were added to medium from day 0-9. For MGE differentiation, SB431542 and LDN193189 were given 
from day 0-9, as well as XAV939 (2 µM; Tocris), a Wnt inhibitor. 
Cells were passaged at day 9-12 as follows. Manual dissociation was carried out with 0.02% EDTA as 
above (2.1.1) but cells were kept in large clusters and titrated very gently without the centrifugation 
step. Cells were split at a 2:3 ratio onto fibronectin-coated plates (15 µg/ml, 1 hour at 37°C; Millipore). 
The 2nd passage was carried out between days 19 and 22 using EDTA as above but with more vigorous 
titration to make very small clusters of cells, which were plated onto poly-D-lysine and laminin-coated 
plates. Poly-D-lysine (10 µg/ml in ddH2O) was added for 30 minutes at room temperature, washed and 
dried under UV. Laminin (10 µg/ml; Sigma) was then added and incubated overnight at 37°C. When 
cells started to look neuronal, at around day 25, B27 with retinol (Gibco) replaced the B27 without 
retinol and growth factors BDNF and GDNF (10 ng/ml; Peprotech) were added to promote neuron 
survival. 
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For MSN differentiation, Activin A (25 ng/ml; R&D) was added from day 10 onwards and cells were 
split 1:1 at passage 2. For MGE differentiation, SHH (200 ng/ml; R&D) and purmorphamine (1 µM; 
Millipore) were added from day 10 to 18 and cells were split 1:3 or 1:4 at passage 2, depending on 
density. Other molecules were given as stated in the relevant chapter: cyclopamine (1 µM), SB525334 
(1 µM), LY2109761 (5 µM). 
For electrophysiology experiments, cells were dissociated with Accutase (Gibco) and seeded at a 
density of 100,000 cells per 13 mm coverslip. SCM1 medium was given for 8 days following the second 
or third passage and was composed as follows: 100 ml DMEM-F12, 50 ml Neurobasal, 1ml N2, 1ml 
B27 w/o RA, 2 mM L-glutamine, 300 µl mycozap, 0.1 mM β-mercaptoethanol, 2 μM PD0332991, 10 
μM DAPT, 0.5 mM CaCl2 (to give 1.8mM total CaCl2 in final complete medium), 200 μM ascorbic acid, 
10 ng/mL BDNF, 1 μM LM22A4, 10 μM Forskolin, 3 μM CHIR 99021, 300 μM GABA. This was replaced 
by SCM2 until the end of the experiment, which was composed of: 25 ml DMEM-F12, 25 ml Neurobasal 
A, 1 ml B27 with RA, 2 mM L-glutamine, 100 μl Mycozap, 0.1 mM β-mercaptoethanol, 2 μM 
PD0332991, 3 μM CHIR 99021, 0.3 mM CaCl2, 200 μM ascorbic acid, 10 ng/mL BDNF, 1 μM LM22A4. 
2.2 Cell analysis 
2.2.1 Immunocytochemical staining 
Cultured cells were washed once with PBS and fixed in 3.7% PFA for 15 minutes at room temperature. 
Fixed cells could be stored up to 2 weeks at 4°C or stained immediately after fixing, as follows. For 
nuclear stains, fixed cells underwent 5 minute methanol washes of ascending then descending 
methanol dilutions (33%, 50%, 66% at 4°C, then 100% at -20°C) in PBS. Permeabilisation was achieved 
by washing with PBS-T (PBS+0.3% Triton-X-100) twice for 10 minutes, then cells were blocked in PBS-
T with 2% BSA and 3% donkey serum for 20-30 minutes at room temperature. Primary antibodies were 
added in PBS-T with 3% donkey serum and left overnight at 4°C. Cells were washed 3 times for 10 
minutes with PBS-T before secondary antibodies (1/200, AlexaFluor anti-donkey 488, 555, 594, 647; 
Life Technologies) were added in PBS-T and left for 1 hour at room temperature. DAPI (1/3000 
dilution; Molecular Probes) in PBS was applied for 5 minutes at room temperature. Stained cells were 
washed 3 times for 10 minutes in PBS before mounting in DAKO fluorescent mounting medium (Life 
Technologies) either onto glass slides (VWR) or in the culture plate covered with a glass coverslip 
(VWR). All primary antibodies used are listed in Table 2.1. 
Stained cells were imaged using Leica DM6000B upright (for slides) or Leica DMI6000B inverted (for 
plates) fluorescent microscopes. Cell counting for each experiment was carried out on pictures taken 
from at least 5 random fields of view, manually using ImageJ software, or automatically using Cell 
Profiler software. Some images were also taken using a Zeiss LSM710 confocal microscope. 
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2.2.2 Quantitative real-time PCR 
2.2.2.1 RNA extraction 
Cultured cells were washed once with PBS and lysed for RNA extraction with 1 ml Tri reagent (Sigma). 
Cell lysates could be stored at -80°C for up to 1 month before continuing with RNA extraction as 
detailed in the manufacturer’s instructions. 
Briefly, samples were thawed and left at room temperature for 5 minutes before adding 200 µl 
chloroform. They were then shaken vigorously for 15 seconds and allowed to stand for up to 15 
minutes at room temperature before centrifugation at 12,000 x g for 15 minutes at 4°C. The aqueous 
(upper) phase containing RNA was carefully transferred to a new tube. Isopropanol (500 µl) was mixed 
with the aqueous phase and left to stand for 5 minutes at room temperature. Samples were then 
centrifuged at 12,000 x g for 10 minutes at 4°C to create an RNA pellet. The supernatant was removed 
and the pellet washed in 1 ml of 75% ethanol, vortexed and centrifuged at 7,500 x g for 5 minutes at 
4°C. The RNA pellet was air dried and resuspended in 20-50 µl of DEPC-treated ddH2O. 
2.2.2.2 DNase treatment 
RNA concentration was measured on a BioSpectrometer (Eppendorf) and 10 µg was made up to a 17 
µl volume with DEPC-treated ddH2O. DNase mastermix containing 2 µl TURBO DNase 10x buffer and 
1 µl TURBO DNase (Ambion) per sample was added to the RNA samples. Samples were incubated at 
37°C for 20-30 minutes and then 2 µl DNase inactivation reagent was added and samples mixed 
regularly for 5 minutes at room temperature. Samples were centrifuged for 1.5 minutes at 10,000 x g 
and supernatant containing DNase-treated RNA was transferred to a fresh tube. 
2.2.2.3 Reverse transcription PCR  
Reverse transcription was carried out as per the manufacturer’s instructions (Invitrogen). RNA 
concentration was measured again and 1 µg added to 1 µl of random primers and 1 µl of dNTP mix, 
then made up to a final volume of 13 µl with DEPC-treated ddH2O. Samples were placed in a 
Mastercycler (Eppendorf) and heated to 65°C for 5 minutes then cooled to 4°C for 1 minute. A master-
mix containing per sample: 4 µl First-Strand buffer, 1 µl 0.1 M DTT, 1 µl RNaseOUT and 2 µl SuperScript 
III RT were added to each RNA mixture. The Mastercycler program was resumed to include the 
following steps: 25°C for 5 mins, 55°C for 60 mins and 70°C for 15 mins. cDNA was then diluted 1/10 
in ddH2O. Three RNA samples were chosen at random to use in a 2nd reaction for no reverse 
transcription controls, without the SuperScript III RT. 
2.2.2.4 Quantitative real-time PCR (qPCR) 
A SYBR MESA green master-mix was used for qPCR, containing per reaction: 10 µl MESA green 
(Eurogentech), 5 µM of the forward and reverse primers for the gene of interest (10 or 100 µM stock; 
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custom-made, Sigma) and made up to 18 µl with ddH2O. The master-mix was distributed into a 96-
well-plate (18 µl per well; Greiner Bio-One) and 2 µl of cDNA from each sample was added to duplicate 
or triplicate wells. The Bio-Rad CFX Connect Real-Time System was used to run the qPCR program: 
94°C for 4 mins, then 40 cycles of [94°C for 30 secs + 60°C for 15 secs + 72°C for 30 secs]. Melting curve 
analysis was performed from 65-95°C, read every 0.2°C. 
Data was collected on CFX Manager software (Bio-Rad) and exported to Microsoft Excel for analysis. 
All qPCR data was normalised to 2 reference genes – GAPDH and β-ACTIN – and relative quantification 
was compared to control basal conditions using the ΔΔ-CT method. Error bars represent the SEM of 
biological replicates (n≥3). 
All primers (Table 2.2) had been previously tested for efficiency on human foetal whole brain tissue 
with serial dilutions and all annealing temperatures were 60°C. 
2.2.3 Electrophysiological analysis 
Neuronal cultures on glass coverlips (days specified with results) were placed in a recording chamber 
perfused with artificial cerebrospinal fluid (aCSF) at a flow rate of 2-2.5 ml/min, which contained (in 
mM): 135 NaCl, 5 KCl, 1.2 MgCl2, 1.25 CaCl2, 10 D-glucose, 5 N-2-265 hydroxyethylpiperazine-N'-2-
ethanesulfonic acid (HEPES) (all from Sigma), pH 7.4. Recording pipettes (4-6 MΩ) were pulled from 
borosilicate capillary glass (Sutter Instruments, USA) and filled with internal solution containing (in 
mM): 117 KCl, 10 NaCl, 11 HEPES, 2 Na2-ATP, 2 Na-GTP, 1.2 Na2-phosphocreatine, 2 MgCl2, 1 CaCl2 and 
11 ethylene-glycol-tetra-acetic acid (EGTA) (all from Sigma), pH 7.2. Cells were visualised using 
infrared differential interference contrast (DIC) videomicroscopy through a Nikon Eclipse FN1 or 
Olympus BX51 microscope. Whole-cell patch clamp recordings were acquired at room temperature 
(20-22°C) using a Multiclamp 700B amplifier and Digidata 1332 or 1550 analogue to digital converter 
with pClamp 10 software (all Molecular Devices, USA). Cells were recorded in current clamp mode and 
injected with current steps of 10 or 20 pA between -100 and +100 pA to measure voltage responses. 
Mean resting membrane potential was calculated using 1 s segments from at least 10 sweeps. Data 
were analysed with Clampfit software (Molecular Devices) then exported to and plotted using Origin 
software (OriginLab, USA). 
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2.3 Transplantation of hESC-derived neural progenitors 
All animal work was done in compliance with the European Directive 2010/63/EU on the protection 
of animals used for scientific purposes, under the project licence of Professor Stephen B. Dunnett (PPL 
30/3036; PIL I0D92ED42). 
2.3.1 Transplantation of hPSC-derived MGE progenitors into neonatal rats (with Claire Kelly) 
2.3.1.1 Cell suspension preparation 
Cells cultured to day 20-22 of MGE differentiation (SHH and purmorphamine added day 10-18) were 
washed with PBS and dissociated with accutase (15 minutes at 37°C). N2B27 medium was added to 
inactivate the accutase and the cell suspension was counted and then centrifuged at 1150 rpm for 3 
minutes. Cells were resuspended in DMEM-F12 to a volume for 2 x 105 cells per µl and transported on 
ice to the surgery room. 
2.3.1.2 Postnatal care of mother and pups 
Pregnant female Sprague-Dawley rats (Charles River) gave birth to litters and were left 1 day to ensure 
they had fed and bonded with their pups. To avoid the mothers rejecting their pups after surgery, the 
mother was removed from her pups before surgery and placed in a separate cage. Once all pups had 
been injected, the mother was put under isoflurane anaesthesia for 3 minutes and then placed back 
in her home cage surrounded by her pups. 
2.3.1.3 Transplantation procedure 
All surgical procedures were carried out under isoflurane anaesthesia using a neonatal adaptor on a 
stereotaxic frame. Post-natal day 2 Sprague Dawley pups were injected with 2 x 105 cells in a volume 
of 1 µl using a syringe. Injection coordinates targeted the right cortex or striatum (0.9 mm anterior 
and 1.8 mm lateral to bregma, 2.0 mm below the dura; 0.7 mm anterior and 1.9 mm lateral to bregma, 
2.9 mm below the dura). Cells were injected over 1 minute and the needle was left in place another 3 
minutes before withdrawal. The scalp was glued together using Vetbond (3M) and pups were placed 
in warm recovery boxes for 10 minutes before being put back in their home cage. 
2.3.1.4 Experimental groups and time points 
Two rounds of transplantation were carried out with two litters per experiment. The first round 
included 23 pups, sacrificed at 4, 8, 16 and 24 weeks (n=2, 2, 4 and 15). The second round included 31 
pups, of which 26 were given daily intraperitoneal Cyclosporine A injections (10 mg/kg; Sandimmun) 
from weaning onwards, and were sacrificed at 6, 12 and 20 weeks (n=6, 9 and 7; 4 rats had to be 
sacrificed early due to illness). The remaining 5 animals were not treated with immune suppression 
and were all sacrificed at 20 weeks. 
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2.3.2 Tissue preparation 
Animals were sacrificed at by giving a lethal dose of Euthatal (Merial) and were trans-cardially 
perfused with pre-wash (1.8% di-sodium hydrogen phosphate, 0.9% sodium chloride, in ddH2O, pH 
7.3) for 2 minutes and PFA (4% diluted in pre-wash) for 5 minutes. The brains were removed and post-
fixed in 4% PFA for another 4 hours before being transferred to 25% sucrose (in pre-wash) for storage 
at 4°C up to 1 week. Coronal sections were cut to 40 µm thickness in 12 series using a microtome 
(RM2245, Leica) with a freezing stage (BFS-3MP Controller, PhysiTemp). Sections were stored in anti-
freeze solution (0.545% di-sodium hydrogen phosphate, 0.157% sodium dihydrogen phosphate, 40% 
ddH2O, pH 7.3; add 30% ethylene glycol, 30% glycerol) at -20°C for up to 6 months before staining. 
2.3.3 Immunohistochemistry 
All steps were performed on a shaker at room temperature. Floating sections were washed 3 times 
for 10 minutes in TBS (1.2% Trizma base, 0.9% sodium chloride, in ddH2O, pH 7.4) and blocked (Triton-
X-100-TBS with 3% donkey serum) for 1 hour. Sections were incubated in primary antibody solution 
(TXTBS + 1% donkey serum + primary antibodies) overnight. Sections were washed 3 times for 10 
minutes in TBS before incubation in secondary antibody solution (TBS + secondary antibodies; 1/200, 
AlexaFluor 488, 555, 594 and 647) overnight. Sections were washed 3 times for 10 minutes in TBS and 
then put in TNS (0.6% Trizma base in ddH2O, pH 7.4) for mounting onto gelatin-coated glass slides. 
Sections were air dried, cover-slipped with VectaShield hardset antifade mounting medium with DAPI 
(Vector Labs) and stored at 4°C. All primary antibodies are listed in Table 2.1. 
2.3.4 Section imaging and analysis 
Imaging of sections was carried out as described for cells (Section 2.2.1). Absolute cell counts were 
performed for HuNu (human nuclei) and NKX2.1 and corrected using the Abercrombie formula: 
P=1/F*N*M/(D+M) 
P = number of cells per graft; N = total raw cell count; F = frequency of sampled sections (1:12); M = 
section thickness (0.04 mm); D = Mean cell diameter. 
NeuN-positive cells were counted as a percentage of GFP and the mean and SEM calculated between 
subjects. Calretinin and nestin are cytoplasmic markers making reliable counting of cells in clumps 
using a widefield fluorescent microscope unfeasible. Only cells separate from the clumps were 
counted for these markers as a percentage of GFP. 
2.3.5 Ex vivo brain slice recording (Michael Laing) 
Coronal slices (300 µm) containing the striatum or hippocampus were prepared from 12-week-old rats 
(12 weeks post-transplantation) in chilled (1-3°C) cutting solution bubbled with carbogen (95% O2/5% 
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CO2) (in mM: 60 sucrose, 85 NaCl, 2.5 KCl, 1 CaCl2, 2 MgCl2, 1.25 NaH2PO4, 25 NaHCO3, 25 D-glucose, 
3 kynurenic acid, and 0.045 indomethacin). Slices were stored for 20 min at 35°C in sucrose-containing 
solution and then maintained at room temperature in aCSF [in mM: 125 NaCl, 2.5 KCl, 1 CaCl2, 2 MgCl2, 
1.25 NaH2PO4, 25 NaHCO3, and 25 D-glucose (305 mOsm)] and used within 4-6 hours. For recording, 
slices were transferred to a submersion chamber continuously perfused with warmed (35°C) aCSF [in 
mM: 125 NaCl, 2.5 KCl, 2 CaCl2, 1 MgCl2, 1.25 NaH2PO4, 25 NaHCO3, and 25 D-glucose (305 mOsm)] at 
a flow rate of 2-2.5 ml/min. Somatic whole-cell patch-clamp recordings were performed on GFP-
positive cells (visually identified by LED fluorescence and infrared DIC videomicroscopy through an 
Olympus BX51 microscope) using pipettes with resistances of 4–6 MΩ when filled with internal 
solution containing (in mM): 130 K-gluconate, 20 KCl, 10 HEPES, 0.16 EGTA, 2 Mg-ATP, 2 Na2-ATP, and 
0.3 Na2-GTP, pH 7.3 (295 mOsm). Electrophysiological data were acquired at 20 kHz and filtered at 6 
kHz using a Multiclamp 700B patch-clamp amplifier and Digidata 1550 analogue to digital converter 
with pClamp 10 software (Molecular Devices). Evoked voltage responses were measured by injecting 
500 ms current steps from 0-300 pA. Mean resting membrane potential was calculated using 1 s 
segments from 10 sweeps. Data were analysed with Clampfit software (Molecular Devices) then 
exported to and plotted using Origin software (OriginLab, USA). These experiments were performed 
by Michael Laing and the data analysed by myself. 
2.4 Statistical analysis 
For cell counting analysis, the mean percentage cells and SEM was calculated from the mean of at 
least 3 independent experiments. A two-way ANOVA was conducted to test for significant differences 
between groups at different time points, with post-hoc Bonferroni correction for multiple pairwise 
comparisons. Where only 2 groups were compared, a one-tailed t-test was used to compare means. 
For qPCR analysis, technical replicates were averaged to give individual biological replicates. The mean 
and SEM of 3 biological replicates was calculated and compared between groups by two-way ANOVA 
with post-hoc Bonferroni correction for multiple pairwise comparisons. 
Mean resting membrane potentials and input resistances were calculated from the stated number of 
cells in Figures 3.4 and 4.3 in each group of a single experiment. Means were compared by two-way 
ANOVA with post-hoc Bonferroni correction for multiple pairwise comparisons.
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Table 2.1: List of primary antibodies used for immunostaining. 
Antigen Species Supplier Code 
Dilution 
Cells Rat tissue 
Calbindin rabbit Swant CB-38a 1/500 1/1000 
Calretinin rabbit Swant 7697 1/500 1/1000 
ChAT goat Millipore AB144 1/100 1/200 
CTIP2 rat Abcam 25B6 1/500  
DARPP32 rabbit Santa Cruz sc11365 1/200 1/500 
Doublecortin goat Santa Cruz sc8067 1/100 1/100 
FOXG1 rabbit Abcam 18259 1/250  
FOXP1 rabbit Abcam 16645 1/200  
FOXP2 goat Abcam ab1307 1/100  
GABA rabbit Sigma  1/500 1/1000 
GAD67 mouse Millipore mab5406 1/500 1/500 
GFAP mouse Dako  1/100 1/100 
GFP rabbit Invitrogen  1/500 1/1000 
HuNu mouse Millipore mab1281 1/250 1/1000 
ISL1 rat DSHB  1/100  
MAP2 mouse Sigma  1/500  
ASCL1 mouse BD 556604 1/500  
MEIS2 goat Santa Cruz 10600 1/500  
Nestin mouse Neuromics  1/300 1/300 
Nestin mouse BD 611659 1/300  
Nestin rabbit Millipore  1/500  
NeuN mouse Millipore mab377 1/250 1/500 
NeuN rabbit Millipore  1/500  
NKX2.1 (TTF1) rabbit Abcam ab40880 1/1000 1/1000 
NOLZ1 (ZNF503) mouse Abnova  1/500  
NPY rabbit Immunostar 22940 1/200 1/250 
Oct4 goat Santa Cruz sc8628 1/500  
OLIG2 goat R&D  1/200  
Parvalbumin mouse Sigma p3088 1/100 1/100 
PAX6 mouse DSHB  1/1000  
Somatostatin rabbit Millipore  1/50  
Somatostatin rat Millipore  1/50 1/100 
STEM121 mouse Stem Cells Inc   1/3000 
TH rabbit Pelfreeze P40101 1/500  
TUJ1 rabbit Covance  1/1000  
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Table 2.2: List of primers used for qPCR. 
Gene Forward primer Reverse primer 
GAPDH ACGACCCCTTCATTGACCTCAACT ATATTTCTCGTGGTTCACACCCAT 
β-ACTIN TCACCACCACGGCCGAGCG TCTCCTTCTGCATCCTGTCG 
CTIP2 CTCCGAGCTCAGGAAAGTGTC   TCATCTTTACCTGCAATGTTCTCC   
GSX2 TCACTAGCACGCAACTCCTG TTTTCACCTGCTTCTCCGAC 
DLX2 TCACTAGCACGCAACTCCTG TTTTCACCTGCTTCTCCGAC 
NKX2.1 CGCATCCAATCTCAAGGAAT TGTGCCCAGAGTGAAGTTTG 
PAX6 AATAACCTGCCTATGCAACCC AACTTGAACTGGAACTGACACAC 
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3 The role of TGFβ signalling in hPSC differentiation towards 
functional MSN fate 
3.1 Introduction 
The generation of MSNs from hPSCs has many potential applications, both scientific and clinical. The 
use of defined factors to induce an LGE phenotype followed by MSN fate allows modification of 
conditions to investigate mechanisms that affect MSN differentiation in vitro and could therefore have 
implications for in vivo development. This would allow the screening of novel pathways in cell culture 
before taking studies into animal models, thereby reducing unnecessary use of animals in research. 
Furthermore, the ability to produce neurons that display functionally mature characteristics would 
allow unprecedented access to healthy human neurons that could be compared against neurons 
derived from patient iPSCs. These in vitro disease models could then be used for studying both disease 
mechanisms and therapeutic targets. Finally, transplantation of foetal tissue into the brains of HD 
patients and animal models has shown promise for the use of cell replacement therapy as a strategy 
for brain repair and the slowing of disease progression. A self-renewing source of tissue is vital for this 
type of therapy to become a viable long term option that can be used with many patients. In order to 
fulfil this potential, a reliable method for generating an enriched population of MSNs from hPSCs is 
crucial. 
Previous work towards differentiating hPSCs into MSNs has focused on ventralising anterior neural 
progenitors produced from stromal cell co-culture, embryoid body or monolayer neural induction 
(Aubry et al., 2008; Ma et al., 2012; Carri et al., 2013; Nicoleau et al., 2013). These groups acted on 
the principle that FOXG1-positive cells in the developing telencephalon are exposed to opposing 
gradients of the ventralising morphogen SHH and the repressor form of GLI3, which is expressed in 
dorsal tissues (Figure 1.3). BMP and Wnt proteins are also expressed in the cortical hem and their 
expression is disrupted in GLI3 mutants (Kuschel, Rüther and Theil, 2003). Aubry et al. built on the use 
of SHH by adding DKK1, an endogenous Wnt antagonist that is also released by floor plate cells (Aubry 
et al., 2008). They later showed that this principle could be applied to the monolayer differentiation 
model, and DKK1 could be replaced with XAV939, a chemical Wnt inhibitor (Nicoleau et al., 2013). This 
approach yielded 28% DARPP32-positive neurons in culture, a more efficient protocol than the similar 
one used by Carri et al., which generated 20% DARPP32-expressing neurons (Carri et al., 2013). Both 
of these studies faced the challenging trade-off between SHH and XAV939 dosage and the increase in 
NKX2.1 expression. While they did lead to up-regulated expression of forebrain and pan-GE markers 
such as FOXG1, OTX2 and GSX2, LGE-specific transcription factor CTIP2 was unaffected at the 
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progenitor stage. Indeed, even using the optimum concentrations of SHH and XAV939, NKX2.1 showed 
a 20-fold increase in expression compared to untreated controls (Nicoleau et al., 2013). LGE-specific 
markers CTIP2, FOXP1 and FOXP2 only appeared alongside DARPP32 expression after neuronal 
maturation. It is therefore likely that the MSNs generated using SHH and Wnt inhibition resulted from 
the induction of pan-GE markers rather than a clear instructive effect towards LGE fate. 
Recently, our lab discovered that Activin A, a member of the TGFβ family of ligands, rapidly induces 
the expression of LGE markers in forebrain progenitors derived from hPSCs (Arber et al., 2015). 
Phosphorylated Smad2 (pSmad2), which is downstream of Activin and TGF-β signalling via the ALK4/5 
receptors, was previously detected in the ganglionic eminences, and co-localised with DLX2 
throughout. The two proteins were also confirmed to interact in vivo by immunoprecipitation, and 
pSmad2 was found to bind to the DLX2 gene enhancer by ChIP (Feijen, Goumans and van den Eijnden-
van Raaij, 1994; Maira et al., 2010). In line with these findings, we saw a >2-fold increase in DLX2 and 
GSX2 mRNA just 12 hours after Activin treatment began. Furthermore, in contrast to previous 
attempts at MSN differentiation, we also observed a large increase in CTIP2 expression. Activin-
treated cells were immuno-reactive for other LGE-specific markers, FOXP2 and NOLZ1, at the 
progenitor stage and matured into 20-40% DARPP32-positive neurons. Despite this robust effect of 
Activin, there is relatively little evidence of it being essential for forebrain development, making it 
difficult to decipher a mechanism by which it induces LGE fate. This provides a good example of how 
this kind of platform can be used to test potential developmentally relevant pathways. 
These initial studies showing generation of hPSC-derived MSNs have presented a very basic 
electrophysiological characterisation of the cells (Ma et al., 2012; Carri et al., 2013; Arber et al., 2015). 
More in depth analysis of the electrophysiological properties of hPSC-derived cortical neurons 
throughout differentiation by Kirwan et al. demonstrated that if cultured for long periods of time, it is 
possible for the cells to form functional synapses and develop mature network and membrane 
properties (Kirwan et al., 2015). Recent advances have been made in enhancing and accelerating the 
functional maturation of hPSC-derived neurons without the need to leave the cells for several months 
or co-culture the cells with primary astrocytes or neurons (Telias, Segal and Ben-Yosef, 2014; Telezhkin 
et al., 2015). These studies used cell cycle inhibitors, neurotrophic factors and increased cAMP levels 
to achieve accelerated maturation. The Telezhkin protocol also focused on the importance of a higher 
extracellular calcium concentration to facilitate GABA-dependent depolarisation and voltage-gated 
Ca2+ entry, promoting CREB phosphorylation and associated neurogenic gene upregulation. Neither of 
these studies did any characterisation as to the fate of the cells, but it can be assumed based on their 
protocols that they produced forebrain neurons. These findings can now be applied to protocols 
inducing specific neuronal subtypes to see if their effects are universal. 
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In this chapter, the mechanism by which Activin exerts its LGE-inducing effects in vitro and whether 
other signalling pathways play a role in this have begun to be deciphered. The ability of the cells to 
become functional neurons in vitro, has also been analysed in more depth, with the hope that this 
could one day progress into forming functional in vitro cell models or in vivo grafts. 
 
3.2 Results 
3.2.1 Activin acts independently of SHH signalling 
Activin and other TGFβ family members have been shown to exhibit a certain degree of promiscuity 
between their family of receptors (Hooi and Hearn, 2005). In order to verify that Activin was acting via 
the ALK4/5 receptors to induce LGE gene upregulation, Activin treatment of forebrain progenitors at 
day 10 was supplemented with an ALK4/5 inhibitor, SB431542 (SB4) (Figure 3.1A). This data forms 
part of a larger dataset with a higher n number included in a previous lab publication, which supports 
the conclusions drawn in this section (Arber et al., 2015). Activin-induced expression of CTIP2 and 
GSX2 by day 19 was abolished in the presence of SB4, confirming receptor-specific activity (Figure 
3.1B). 
With the aim of exploring a potential role of SHH signalling in the LGE-inducing effects of Activin, either 
SHH or its inhibitor, cyclopamine, were added to Activin treatment. Neither molecule had any effect 
on CTIP2 or GSX2 expression levels at day 19, although DLX2 mRNA was doubled only in the SHH 
condition. NKX2.1 expression was also doubled by the presence of SHH while Activin alone actually 
reduced its mRNA levels. These findings were further corroborated by immunostaining for NKX2.1 and 
MSN markers CTIP2 and DARPP32 (Figure 3.1C). No NKX2.1 staining was observed in Activin only 
conditions at d18, whereas the addition of SHH caused a visible increase in the number of NKX2.1-
positive cells. Although not quantified, MSN marker expression induced by Activin appeared to be 
unaffected by the addition of SHH both at the progenitor stage (day 23) and in mature neurons (day 
35), which was in line with the qPCR data. 
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Figure 3.1: Activin exerts LGE-inducing effects independently of SHH 
A) Schematic timeline of MSN differentiation of H7 cells, with the different conditions colour-coded to the graphs 
in (B). B) qPCR data from RNA extracted from day 19 samples after treatment with Activin (25 ng/ml) alone or 
plus SB431542 (10 µM), cyclopamine (1 µM) or SHH (200 ng/ml) as shown in (A). Data show mean RQ ± SEM 
relative to control (n = 6 (control), 6 (Act), 2 (Act+SB), 4 (Act+cyclop) and 2 (Act+SHH), respectively). C) 
Immunostaining of day 18, 23 and 35 differentiated cells treated with Activin alone or plus SHH (Scale bar 100 
µm). 
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3.2.2 Activin acts selectively via ALK5 receptor 
With the aim of teasing apart the different TGFβ pathways that could be activated by treatment of 
hPSC-derived forebrain progenitors with Activin, a screen of three chemical inhibitors selective for 
different ALK receptors was given with Activin from day 10. SB525334 (SB5) is an ALK5 inhibitor that 
also inhibits ALK4 with 4-fold less potency, but is inactive at ALK2/3/6. LY2109761 (LY) is a selective 
dual ALK5 (TGFβ-RI)/TGFβ-RII inhibitor. LDN193189 (LDN) is a selective ALK2/3/6 inhibitor that only 
affects BMP signalling. Cells were treated with Activin with or without inhibitors from day 10 of 
differentiation, and then lysed for RNA extraction 1, 3 or 6 days later (Figure 3.2A,B). Levels of mRNA 
from all conditions and time points were normalised to the control condition at 1 day (differentiation 
day 11). 
After 24 hours, Activin alone induced an increase in expression of CTIP2, GSX2 and NKX2.1 by 2.9, 2.5 
and 3.5-fold respectively compared to the untreated control condition (Figure 3.2B). This effect was 
mostly abolished by all of the inhibitors, with LDN consistently showing the least inhibition across all 
genes. At the 3-day time point, there was very little change in gene expression from control, aside 
from a small increase in GSX2 levels in the Activin and control conditions. 
At 6 days, the level of CTIP2 rose by 6-fold in the Activin condition, which was completely inhibited by 
SB5 and LY, the TGFβ/Activin pathway inhibitors (Figure 3.2B). Surprisingly the addition of LDN to 
Activin caused an 18-fold increase in CTIP2 mRNA levels, although this was also completely abolished 
by the further addition of both SB5 and LY. GSX2 expression increased 11-fold in the control condition, 
whereas Activin alone only led to a 7.6-fold increase. Again, Activin plus LDN saw a modest increase 
in GSX2 compared to the control, of 13.2. NKX2.1 mRNA levels dropped to nearly undetectable levels 
in all conditions. PAX6 expression was consistently higher than the subpallial markers from the first 
time point, but remained constant in all conditions across all time points. 
The unexpected result from the Activin plus LDN condition was verified using a second qPCR 
experiment repeating the control, Activin and Activin plus LDN conditions at 1 and 6 days after starting 
treatment (Figure 3.2C). Activin caused a 3-fold upregulation of CTIP2, which was found to not be 
significantly different from the control condition at either time point. The addition of LDN, however, 
caused a significant 5.8-fold increase in CTIP2 mRNA compared to all conditions after 1 day and the 
control condition at 6 days. Again, there was a large and significant upregulation of GSX2 in the control 
condition (39.6-fold), which was closely matched by the Activin treatment. Activin plus LDN caused a 
further increase (56.7-fold), which was significantly different from both control and Activin alone. 
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Figure 3.2: Activin exerts its effects selectively via the ALK5 receptor. 
A) Schematic timeline of MSN differentiation of H7 cells, with the legend of the different conditions used in (B) 
and (C). B) qPCR data from RNA extracted 1, 3 or 6 days after treatment that began on day 10 of differentiation. 
Cells were untreated (control) or treated with Activin (25 ng/ml), or Activin plus SB525334 (1 µM), LY2109761 (5 
µM) or LDN193189 (100 nM). Data show mean RQ relative to the 1 day control (n = 2). C) A repeat of the 
experiment in (B) with just control, Activin and Activin plus LDN conditions to confirm the LDN effects on CTIP2 
and GSX2 upregulation. Data show mean RQ ± SEM relative to the 1 day control (n = 3; **P<0.01, ***P<0.001; 
two-way ANOVA with post-hoc Bonferroni). 
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3.2.3 Inhibition of BMP signalling accelerates Activin effects 
The unexpected finding that inhibition of BMP signalling by LDN could enhance LGE gene upregulation 
by Activin prompted further enquiry into its effects on protein expression at the MSN stage of 
differentiation. Day 10 differentiated H7 hESCs and i900 human iPSCs cells were treated with Activin 
with or without LDN (100 nM). Activin treatment in both conditions continued throughout the 
experiment, while addition of LDN was stopped at day 20 based on a preliminary experiment. Cells 
were fixed for immunostaining at days 20, 25, 30, 35 and 40 (Figure 3.3A) and cell fate markers were 
counted as a proportion of DAPI (Figure 3.3B,C,D). 
The percentage of NeuN-positive cells increased between days 30 and 40 in all conditions, from 
around 60% to 80%. There was no significant difference in the number of neurons between any of the 
groups at any time (Figure 3.3B). In H7 cells, there was no difference in the percentage of CTIP2 or 
DARPP32-positive cells between the conditions at days 20, 25 and 40 (Figure 3.3C). However, at days 
30 and 35 there was a significant 10% increase in the number of CTIP2-positive cells with LDN 
compared to Activin alone. This was also seen in the number of DARPP32-positive cells, which was 
more than doubled at day 30. There was a final increase in CTIP2 and DARPP32 numbers in the final 5 
days of differentiation in both conditions, causing the Activin cultures to catch up in the number of 
cells expressing both markers. 
In contrast to these findings, the number of CTIP2 and DARPP32-positive neurons from the i900 cell 
line remained equal between the conditions from day 20 to 30 (Figure 3.3C). At day 40, however, 
while the proportion of CTIP2 in the Activin condition appeared to plateau, LDN caused a 17% increase 
in the number of positive cells. Although there were 5% more DARPP32-positive cells with LDN at day 
40, this was not significant. 
There was no effect on other markers that were looked at with immunostaining, including Islet1, 
Meis2, FOXP2 and NOLZ1, nor other neuronal fate markers such as TH, SST or PV. The only marker 
that did seem to change was the proportion of calretinin-positive cells. The Activin protocol routinely 
produces around 3% calretinin neurons, but the H7 LDN condition saw this proportion double to 6% 
by day 40 (Figure 3.3D). In the i900 cultures, the number of calretinin cells was much higher in Activin 
than with LDN at day 30 (8 and 3% respectively), but this had equalised by day 40 at around 7% for 
both conditions. 
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Figure 3.3: LDN accelerates the effects of 
Activin. 
A) Cells immunostained on day 30 and 40 of 
differentiation after treatment from day 10 with 
Activin alone or plus LDN193189 (100 nM) from 
day 10-20. (Scale bar 100 µm.) B) NeuN-positive 
cells were counted as a percentage of DAPI at 
each time point for both cell lines. C) H7 and 
i900-derived cells positive for CTIP2 and 
DARPP32 were counted as a percentage of DAPI 
at each time point. D) Calretinin-positive cells 
were counted as a percentage of DAPI at day 30 
and 40 for both cell lines. Data show mean 
percentage ± SEM of positive cells from 3 independent experiments (* and # denote significant differences 
between the conditions and the time points, respectively, with the coloured # indicating where just one condition 
has changed. *P<0.05, **P<0.01, ***P<0.001; two-way ANOVA with post-hoc Bonferroni).  
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3.2.4 Electrophysiological characterisation of hESC-derived MSNs in vitro 
It has been shown recently that the addition of a combination of small molecules and factors can help 
to enhance maturation of hPSC-derived neurons in vitro, by mimicking the supportive effects of 
astrocytes (Telezhkin et al., 2015). In order to demonstrate the potential of hESC-derived DARPP32-
positive cells to become functional neurons that can be used to model synaptic or network properties 
of MSNs, the cells were plated at low density on day 30 of the MSN differentiation protocol. Immature 
neurons were given SCM1 medium for 8 days, followed by SCM2 medium for the remainder of the 
culture time. A control group was also given the usual basal N2B27 medium with BDNF and GDNF. 
Electrophysiological properties were recorded by whole cell patch clamp recordings from neurons at 
days 45 and 90 of differentiation (Figure 3.4A). Cells did not show any obvious reduction in expression 
of DARPP32 or CTIP2 in response to the SCM media, meaning that approximately 30% of cells patched 
should be DARPP32-positive (Figure 3.4B). 
The mean resting membrane potential (RMP) was the same between basal and SCM at day 45 (-31.5 
mV and -29.1 mV respectively). At day 90 however, the SCM group had an average of -37.9 mV, 
significantly lower than -30 mV in the basal medium (Figure 3.4C). Having observed that a subset of 
the cells recorded fired induced action potentials (APs) upon current injection (iAP) while others 
showed no activity at all (nAP), the groups were split into iAP and nAP to look at whether this would 
alter the mean RMP (Figure 3.4D). Indeed, there was an overall significant difference between iAP and 
nAP cells at all time point and in both basal and SCM conditions. Interestingly, the SCM groups at day 
90 had the same mean RMP regardless of whether they fired APs or not. At day 45, there was no 
difference in mean input resistance between basal and SCM (580 mΩ and 586 mΩ respectively) (Figure 
3.4E). By day 90, the mean input resistance of cells in the basal medium had reduced to 342 mΩ, while 
SCM cells showed a further significant decrease to 195 mΩ. 
Cells were recorded in current clamp and injected with current steps of 10 or 20 pA between -100 and 
+100 pA. At day 45 only 1 cell in each condition fired any spontaneous APs, and 3 cells fired at least 1 
AP following current injection (Figure 3.5A). Two cells in each condition responded with trains of more 
than 2 APs (Figure 3.5B). At day 90, cells in the basal condition had lost all spontaneous activity and 
only 1 cell fired a full AP upon stimulation. In the SCM condition, more spontaneous activity was 
observed than at day 45, with 2 cells firing full APs, 2 attempting APs and 2 cells showing evidence of 
synaptic activity in the form of post-synaptic potentials (PSPs). All but 3 cells fired APs upon current 
injection, however the majority of APs occurred as “rebound spikes” following the negative current 
steps (Figure 3.5B). Having observed the increase in activity when depolarising back to RMP from a 
negative current step, each SCM cell was held at -60 mV and the current step protocol repeated to 
detect any changes in activity. Cells displayed more spontaneous activity, with 2 cells showing 
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repetitive firing and 6 cells firing sporadic APs. There was also increased activity during the current 
steps, with only 1 cell failing to fire a full AP, and the majority at least attempting to fire a train of APs 
(Figure 3.5B,C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: hESC-derived MSNs display neuronal 
membrane properties in vitro. 
A) Schematic timeline of SCM protocol. Activin-
treated young neurons were plated at day 30 and 
cultured in SCM1/2 or basal medium until recording 
at days 45 and 90. B) Basal or SCM cultured cells 
fixed at day 60 and immunostained for MSN 
markers. C-E) Box plot diagrams comparing the 
resting membrane potential (RMP) of each group 
(C); the RMP of cells that fired on current injection 
(iAP) and those that were inactive (nAP) (D); and the 
input resistance of all groups (E). Box plots show 
median with 25th and 75th percentiles (box) and 
outliers (whiskers), as well as the mean (square) (n cells = 10 (Basal d45), 9 (SCM d45), 14 (Basal d90) and 15 
(SCM d90). Two-way ANOVA with post-hoc Bonferroni; *P<0.05, **P<0.01, ***P<0.001). 
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Figure 3.5: hESC-derived MSNs display spontaneous and evoked neuronal activity in vitro. 
A) Pie charts showing the proportion of cells in SCM and basal conditions that displayed spontaneous or evoked 
activity at days 45 and 90 from their RMP (left and middle), and SCM at day 90 from a holding potential of -60 
mV (right). Basal n=10 (d45),14 (d90); SCM n=9 (d45), 15(d90). B) Representative traces of SCM cells at days 45 
and 90, showing voltage responses to consecutive current steps. C) Example traces of SCM day 90 cells displaying 
repetitive firing when held at -60 mV (left); spontaneous AP firing from resting (middle); and spontaneous post-
synaptic potentials (PSPs) while held at -60 mV (right). 
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3.3 Discussion 
In this chapter I have begun to dissect the different components that could be contributing to the 
mechanism by which Activin induces LGE characteristics in hPSC-derived forebrain progenitors. 
Activation of SHH signalling has typically been the approach taken for the generation of MSNs from 
hPSCs, however the data presented here, which is included in a larger dataset that has been published, 
depicts Activin as a distinct pathway completely independent of SHH (Arber et al., 2015). Neither 
blockade of SHH signalling, nor addition of SHH, had any impact on the increased expression of LGE-
specific genes induced by Activin treatment. Indeed, Shh knockout mouse embryos retain expression 
of LGE markers Dlx2 and Gsx2, albeit displaced ventrally in the absence of an Nkx2.1-expressing MGE 
(Rallu et al., 2002). This shows that LGE formation is possible in the absence of Shh activation and 
indicates an alternative pathway by which LGE induction can still occur. Conversely, a study using a 
zebrafish model of development demonstrated that the presence of Nodal, a TGFβ family member 
that shares receptors with Activin, is necessary for Shh expression across the CNS and likely acts 
upstream of Shh to establish dorso-ventral patterning of the telencephalon (Rohr et al., 2001). Ventral 
expression of the zebrafish NKX2.1 homologue, nk2.1b, was abolished in Nodal signalling-deficient 
embryos, but could be partially restored through ectopic Shh expression. Another group more recently 
showed that Smad3, an intracellular effector of TGFβ, Nodal and Activin signalling, is highly expressed 
in the subpallium throughout development, further highlighting the importance of these signalling 
pathways (Casari et al., 2014). It would be worth looking at whether SHH or any component of its 
downstream signalling pathway is upregulated in Activin-treated cultures. 
The use of two TGFβ-RI (ALK5) inhibitors with slightly differing selectivity for other ALK receptors 
indicated that Activin exerts its effects via both ALK5 and ALK4, as SB5, which inhibits both ALKs, was 
consistently more effective at inhibiting LGE marker up-regulation than LY. Furthermore, SB4 in earlier 
experiments demonstrated a complete abolishment of LGE marker expression, both at the mRNA and 
protein levels. This is in agreement with the fact that Activin binds to both receptors in vivo and that 
they have the same intracellular effector proteins, Smad2/3, which should have the same 
transcriptional targets (Piek, Heldin and Ten Dijke, 1999). 
Through the screening of 3 TGFβ family inhibitors, it was found that blocking BMP signalling could 
enhance Activin-induced upregulation of LGE markers CTIP2 and GSX2. While the bulk of the CTIP2 
increase occurred at the later time point, with LDN comfortably doubling the effect of Activin, GSX2 
levels increased earlier in Activin and appeared to be caught up by the control around day 3. LDN 
maintained higher levels of GSX2 by day 6. These differences in gene expression could be put down to 
either LDN improving the differentiation of the cells towards the LGE lineage and potentially increasing 
the final number of MSNs, or simply that the LDN changed the kinetics of the differentiation causing 
52 
gene expression levels to increase and decrease at different times between the conditions. This was 
tested by looking at MSN markers at different time points in 2 cell lines. Our MSN differentiation 
protocol is extremely robust and has been repeated many times in the H7 cell line (Arber et al., 2015). 
From this, we know that the peak of DARPP32 expression is by day 40, so this was the last time point 
in this experiment. Indeed, in H7 cells, the increase in CTIP2 and DARPP32 in the middle time points 
suggests that blockade of BMP signalling accelerates the MSN differentiation, but cannot improve the 
final outcome. It is important to note that there was no effect of LDN on the number of NeuN-positive 
cells, showing that it is not simply an improvement of neural induction by Smad inhibition. The results 
from the i900 cells contrast with these findings, the level of CTIP2 remained equal up until day 40, 
when they diverged. It is unknown whether this would have plateaued, as in the H7 cell line, or 
continued to rise further. It would be interesting to verify this result, as it would mean that the addition 
of LDN until day 20 could cause a difference in CTIP2 expression 20 days after treatment had ended. 
It is not surprising that LDN also had an effect on the number of calretinin-positive neurons, as we 
previously showed that late treatment of forebrain progenitors with Activin produces CGE-derived 
calretinin interneurons (Cambray et al., 2012). 
BMPs are heavily involved in dorsal neural tube development, but are specifically expressed in the 
dorsal midline of the forebrain (Hu et al., 2008). It is therefore possible that the enhancement of 
Activin-induced CTIP2 and GSX2 expression by BMP receptor inhibition is down to the suppression of 
a dorso-medial telencephalic fate, encouraging the cells more ventro-lateral towards an LGE fate. The 
default fate for the dual Smad inhibition neural induction protocol is dorsal forebrain fate, with high 
PAX6 expression and eventually the expression of mature cortical layer markers (Chambers et al., 
2009). Neither treatment with Activin alone or with LDN appeared to affect the expression of PAX6, 
although there is some PAX6 expression in the LGE so other dorsal markers would need to be analysed 
to test this theory. It is likely that inhibition of BMP signalling could simply reduce the lineage options 
for neural progenitors to take, leading to an increase in CTIP2-positive LGE progenitors. 
As Activins and BMPs share some common Type II receptors (ActR-II and ActR-IIB), it is also possible 
that LDN, which inhibits BMP Type I receptors ALK1/2/3/6, causes more Type II receptors to be 
available for Activin to bind and increase Smad2/3 phosphorylation (Piek, Heldin and Ten Dijke, 1999). 
Indeed Smad2 has been shown to directly interact with the GSX2 gene, supporting the result that LDN 
increased GSX2 expression (Maira et al., 2010). Previous unpublished work in our lab into the dose 
response of Activin showed that increasing the concentration of Activin could further increase the 
expression of LGE markers. So increasing receptor availability or non-specific binding is another likely 
explanation for this effect. 
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It is worth noting that we have shown previously that adding Activin from differentiation day 10 to 20 
is crucial for obtaining a high proportion of DARPP32-expressing neurons in the H9 hESC line; any 
longer than this continues to increase the proportion of CTIP2-positive cells but has no effect on 
DARPP32 expression (Arber et al., 2015). The data from the H7 cells support this, as increased 
expression can be seen in the middle of the differentiation, but there appears to be a maximum 
possible proportion of both CTIP2 and DARPP32. The i900 cells did show a higher proportion of CTIP2-
positive cells in the LDN condition at day 40, which may indicate that their differentiation kinetics are 
different from H7, taking longer for the effects to be detected. However, from observing the cells in 
culture they actually appeared to mature faster than their H7 counterparts, and tended to express 
mature MSN markers in higher proportions, so it is unclear what led to these differences. These 
findings require further clarification by testing firstly whether Activin increases the phosphorylation 
of Smad2/3 in these cultures, and if so, whether LDN further upregulates this phosphorylation. 
We have provided much evidence that Activin robustly generates neurons from hESCs that express 
the correct proteins and mRNA to be defined as striatal MSN-like (Arber et al., 2015). Moving forward, 
if these cells are to be used as a source of tissue for transplantation or in vitro modelling of disease or 
striatal function, they must also become electrophysiologically active and mimic certain characteristics 
of real MSNs. Patch clamp recordings from rat MSNs in acute brain slices show that they have a 
relatively hyperpolarised RMP of around -80 mV and an average input resistance of 193 MΩ 
(Kawaguchi, 1993). However, human foetal neurons from 20-22 weeks gestation have shown RMPs of 
-45-55 mV and input resistances of 0.9-2.5 GΩ, which may be more indicative of what can be expected 
of hPSC-derived neurons (Moore et al., 2011; Nicholas et al., 2013). There has been very little work 
done on hPSC-derived MSN electrophysiology, with focus being on developing methods for their 
production (Carri et al., 2013; Arber et al., 2015). The HD iPSC consortium described some deficits in 
action potential firing in iPSC-derived neurons from HD patients, but the proportion of DARPP32-
expressing MSNs in the cultures was very low (The HD iPSC Consortium, 2012). SCM media described 
by Telezhkin et al. had no effect on hESC-derived MSNs at day 45 of differentiation compared to the 
usual basal differentiation medium. This is in contrast to their findings, which demonstrated significant 
improvements in membrane properties by day 36 (Telezhkin et al., 2015). However, individual cell 
lines have distinct differentiation and maturation kinetics, so cells were recorded from again at day 
90. At this later time point, cells in the basal condition had lost most of their functionality, perhaps 
indicating a decline in the health of the cells. Neurons in the SCM medium were almost all able to fire 
action potentials either from resting or after being held at -60 mV. Cells from either condition that 
were able to fire action potentials had a RMP of around -40 mV, with the most hyperpolarised cell 
resting at -45 mV. This is in line with the kinds of values observed by Telezhkin et al., whereas Song et 
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al. managed to produce neurons with RMPs of -70 mV after just 3 weeks in culture (Song et al., 2013; 
Telezhkin et al., 2015). Interestingly, Kirwan et al. showed that 4 different hPSC lines differentiated in 
exactly the same way could have very different RMPs, ranging from -40 mV to -55 mV, while also 
exhibiting very similar firing properties (Kirwan et al., 2015). A key finding in the data presented here 
is that despite the inability of positive current injection to stimulate an action potential, in returning 
to baseline from a negative current step the majority of cells fired at least one action potential. This is 
likely due to the inactivation of voltage-gated sodium channels held at depolarised membrane 
potentials of -40 mV or above (Bean, 2007). This means that when the cell is hyperpolarised by 
negative current injection the channels can reactivate, then as the current step ends the membrane 
potential returns to its RMP allowing the channels to open as the membrane reaches the action 
potential threshold. This also means that action potentials fired in these conditions often had a larger 
amplitude as they were able to recruit more sodium channels. Artificially holding the membrane 
potential in a hyperpolarised state by injecting negative current may be a good way to observe some 
of the more interesting properties of the neurons, such as synaptic events and spontaneous activity. 
Input resistance in our cells was relatively low compared to other studies, and it decreased over time 
and further with addition of SCM media. Even Telezhkin et al. showed an average input resistance of 
around 800 MΩ, while others consistently observed measurements of more than 2 GΩ. This could be 
another difference between cell lines or represent neuronal subtype-specific differences in ion 
channel expression. 
The desire to obtain homogeneous cultures may be holding back this particular aspect of neuron 
differentiation from hPSCs, as this completely ignores the heterogeneity of the developing brain. The 
motivation behind the Telezhkin et al. study was to design a fully-defined medium that could enhance 
maturation of hPSC-derived neurons by mimicking the positive effects of astrocyte conditioned 
medium (Rushton et al., 2013; Telezhkin et al., 2015). However, while achieving a homogeneous 
culture of functional neurons in a matter of weeks may be beneficial for high throughput analysis of 
different cell lines or drug screening, it may not be useful for more complex studies modelling brain 
function due to the absence of astrocytes and the tripartite synapse. The opportunity to observe the 
activity of human neurons in vitro is certainly worth maximising and more work must be done to devise 
optimal culture paradigms by which to study their function. This should include high throughput 
methods such as this one, as well as more complex co-culture systems involving all the relevant cell 
types for a certain brain region or circuit. 
Data presented in this chapter have shown that Activin selectively activates ALK4/5 receptors, 
sufficient to upregulate CTIP2 and GSX2 expression independently of SHH signalling. Evidence is also 
shown suggesting that this effect may be marginally enhanced by inhibiting BMP Type I receptors. 
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Basic electrophysiological characterisation of the cells has demonstrated that they can become 
functional enough to study membrane and synaptic properties, but further analysis will show whether 
the cells have MSN-specific characteristics such as the response to dopamine release or susceptibility 
to excitotoxicity. 
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4 Characterisation of hPSC-derived MGE-like interneurons 
4.1 Introduction 
Striatal interneurons are often ignored when discussing striatal function or the impact of HD. Most of 
our knowledge comes from studies in rodents, whose interneurons comprise only 5% of neurons in 
the striatum. In contrast, human and primate interneurons make up 23% of striatal neurons 
(Graveland and Difiglia, 1985; Wu and Parent, 2000). This is a large disparity, and indicates a more 
important role for primate interneurons compared to rodents’. It would be useful to generate human 
striatal interneurons from hPSCs for the ability to study them in vitro and transplanted in rodent 
striatum for a direct comparison between species. The more cell types we can produce in vitro, the 
more complex culture systems we may be able to exploit for modelling either striatal function alone 
or in networks with other neuronal subtypes such as cortical, pallidal or nigral neurons. Striatal 
interneurons originate in the MGE, along with cortical and hippocampal interneurons, and neurons of 
the globus pallidus, septum, pre-optic area, amygdala and basal forebrain (Marin, Anderson and 
Rubenstein, 2000; Flandin, Kimura and Rubenstein, 2010). Distinct mature markers define the 
different subtypes of interneurons and projection neurons produced in the MGE, of which ChAT, PV 
and SST are the main subpopulation identifiers (Figure 1.3). A small proportion of CR interneurons are 
also produced in the MGE, some co-expressing SST, but the majority are born in the nearby CGE. 
Before their migration away from the MGE, progenitors can be identified by their combinatorial 
expression of NKX2.1, OLIG2, ASCL1 and DLX1/2, followed by post-mitotic expression of LHX6 or LHX7 
for GABAergic or cholinergic neurons respectively (Marin, Anderson and Rubenstein, 2000; Nóbrega-
Pereira et al., 2010). 
Although loss of striatal MSNs represents the most marked cell loss in HD, PV interneurons are also 
diminished by up to 80% in symptomatic HD patients (Reiner et al., 2013). Other interneuron subtypes, 
such as SST, NPY, CR and cholinergic, are spared, although CR and ChAT expression are lost in surviving 
large cholinergic interneurons, causing previous confusion as to their fate (Massouh et al., 2008). 
There is uncertainty as to which interneuron subtypes survive the quinolinic acid (QA) lesion, used to 
produce the majority of non-transgenic rodent HD models. Previous work demonstrated that PV 
interneurons were spared 2 months after intrastriatal QA injection while SST interneurons were lost 
(Figueredo-Cardenas et al., 1998). Conversely, a more recent study showed that both PV and SST/NPY 
interneurons were severely reduced, while CR and ChAT interneurons were spared (Feng et al., 2014). 
It has been shown that the age of the rats receiving the QA lesion can affect the survival or loss of SST 
interneurons, which may also extend to PV interneurons, potentially explaining the different findings 
between studies (Figueredo-Cardenas, Chen and Reiner, 1997). Despite this ambiguity in the QA 
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rodent HD model, the huge difference in proportion of striatal interneurons between rodents and 
humans suggests that such a reduction in parvalbumin interneurons in HD patients will play a big part 
in symptom progression. This is particularly relevant to the dystonia associated with HD, as loss of PV 
striatal interneurons in rodent models has been shown to cause dystonia (Reiner et al., 2013). It is 
therefore likely that replacement of all cell types will be required to restore striatal function in HD 
patients, even if this is not necessary for animal models of HD. 
Indeed, transplantation of hESC-derived MSNs alone has so far yielded little functional improvement 
in HD rodent models (Carri et al., 2013; Nicoleau et al., 2013; Arber et al., 2015). The only study that 
has shown substantial functional improvement was by Ma et al., in which 4% of cells in 4-month-old 
grafts were interneurons that expressed ChAT (1.5%), PV (1%), CR (1%) and SST (0.5%), due to their 
use of SHH as a patterning factor (Ma et al., 2012). This is remarkably close to the real percentage of 
interneurons present in the rat striatum (Wu and Parent, 2000). This may have contributed to the 
significant motor improvement seen in the QA-lesioned mice, either by replacing both MSNs and 
interneurons into the lesioned striatum, or by providing the grafted MSNs with target cell types such 
as interneurons or globus pallidus projection neurons, which are also derived from MGE cells. These 
are possible mechanisms that could be further explored by achieving differentiation of both MSNs and 
interneurons from hPSCs as separate, defined populations, then studying their behaviour when 
cultured or grafted separately and together. 
In addition to striatal interneuron changes in HD, there is also evidence of their dysfunction in PD. 
Mice over-expressing human α-synuclein experienced early loss of the ability to induce long term 
potentiation of cholinergic interneurons, but this was fully restored with 3 days of L-DOPA treatment 
(Tozzi et al., 2015). Similarly, 3 days of dopamine depletion in mice led to a doubling of connectivity 
between fast-spiking PV interneurons and indirect pathway MSNs. Computational modelling of the 
striatal micro-circuit revealed that this increase in feed-forward inhibition could result in increased 
synchrony in indirect pathway output (Gittis et al., 2011). This may explain the increased synchrony 
and oscillations seen in the subthalamic nucleus and globus pallidus of PD patients. 
Dysfunction or imbalance of MGE-derived cortical interneurons is heavily implicated in 
neurodevelopmental disorders such as epilepsy, schizophrenia and autism, instigating extensive 
research into their derivation from hPSCs (Maroof et al., 2013; Nicholas et al., 2013; Cunningham et 
al., 2014; Tyson et al., 2015). However, no one has yet tried to use these same MGE-like progenitors 
generated from hPSCs to produce striatal interneurons. The typical markers used to distinguish 
between interneuron subtypes are almost useless in informing whether cultured interneurons are 
cortical, hippocampal or striatal in nature. PV, SST and CR interneurons are all found in these regions. 
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Cholinergic interneurons are solely striatal, and derived from the MGE, but distinguishing these from 
basal forebrain cholinergic projection neurons with any confidence would also be a challenge. The 
studies described in Section 1.2.4 named some guidance molecules that are differentially expressed 
in each population, however the antibodies they used are not commercially available (Villar-Cerviño 
et al., 2015). Immunohistochemistry performed on brain sections from human foetuses confirmed 
that migrating interneurons lose NKX2.1 expression by the time they have migrated through the LGE, 
and switch on the post-mitotic MGE marker LHX6. Meanwhile, interneurons that settle in the striatum 
appear to maintain expression of both transcription factors, which would be one way to distinguish 
between cortical and striatal interneurons, but we have been unable to find a LHX6 antibody that 
works in our hands (Hansen et al., 2013).  
In vitro, without target brain regions to migrate to, it is difficult to identify the true fate of the MGE-
like cells derived from hPSCs. Hence, transplantation into the neonatal brain is one good way to assess 
the capacity of the cells to differentiate and integrate into appropriate brain regions in vivo, which will 
be addressed in Chapter 5. Hypothesising that hPSC-derived MGE progenitors would differentiate into 
striatal as well as cortical interneurons, the aim of the experiments described in this chapter was to 
adapt a monolayer differentiation protocol for cortical interneurons published by Maroof et al. to our 
culture conditions and characterise it using qPCR, immunocytochemistry and electrophysiology 
(Maroof et al., 2013). 
4.2 Results 
4.2.1 Activation of SHH signalling induces MGE fate in hPSCs 
Human ESCs were differentiated using the protocol described by Maroof et al. adapted to our neural 
induction method by Smad inhibitors LDN193189 and SB431542 in N2B27-defined medium. The 
addition of XAV939, a Wnt inhibitor, from day 0-9 has been shown to effectively promote forebrain 
identity and FOXG1 expression (Maroof et al., 2013). SHH and purmorphamine, a SHH agonist, were 
added following the first passage from day 10 to 18 (Figure 4.1A). This induced very strong expression 
of the MGE marker NKX2.1 – almost 9000-fold higher mRNA levels were detected in SHH-treated 
versus untreated controls and 63% of cells were immuno-reactive for NKX2.1 (Figure 4.1B,D,E). Pan-
GE marker DLX2 mRNA was also substantially increased by 60-fold, whereas the LGE marker CTIP2 was 
only increased 3-fold. FOXG1 was expressed in 42% of cells at day 20, while MGE-enriched 
transcription factors OLIG2 and ASCL1 were expressed by around 20% of cells (Figure 4.1C,E). The 
majority of cells were also Nestin positive, a marker for neural progenitors.  
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Figure 4.1: SHH activation induces MGE fate in hESCs 
A) Schematic timeline of MGE differentiation of hESCs. SHH (200 ng/ml) and purmorphamine (1 µM) were applied 
from day 10-18 and BDNF (10 ng/ml) from day 25 onwards. B) Cells immunostained on day 20 of differentiation 
with NKX2.1, Nestin, FOXG1, OLIG2 and ASCL1 in SHH and control conditions. C) qPCR data from cells lysed on 
day 18 of differentiation following 8 days of SHH+purm treatment, relative to control. Data show mean RQ (n=2). 
D) Day 20 cells that stained positive for MGE markers were counted as a percentage of DAPI. Data show mean ± 
SEM from n = 4 (NKX2.1), 1 (FOXG1 and ASCL1) and 3 (OLIG2) independent experiments. Scale bars: white, 200 
µm; yellow, 100 µm; green, 20 µm. 
 
4.2.2 MGE progenitors mature into cortical and striatal interneurons 
MGE progenitors were kept in culture until day 60 and immunostained for several interneuron 
subtype markers. At this stage, all of the main mature markers of MGE-derived cortical and striatal 
interneurons were present (Figure 4.2A-C). Somatostatin and parvalbumin are the most abundant 
types of MGE-derived interneurons, and were found in 7.3 and 5.5% of cells, respectively (Figure 
4.2A,C). Calretinin interneurons are another common subtype found in the cortex and striatum, the 
majority of which are born in the CGE, but made up 3% of cells in these cultures (Figure 4.2B,C). ChAT 
is a cholinergic neuron marker found to be expressed in a small number of cells at day 60, which 
identifies an important striatal interneuron subtype as well as basal forebrain projection neurons. 
Calbindin is another GABAergic interneuron marker that was abundantly expressed. MAP2, a mature 
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neuronal marker, was highly expressed throughout the cultures, as was GAD67, a protein specific to 
GABAergic neurons (Figure 4.2B). NKX2.1 expression still appeared to be very high, but had fallen by 
more than 20% compared to differentiation day 20 (Figure 4.2D). 
These results show that hPSCs can be efficiently patterned towards MGE progenitor identity and 
mature into the various neuronal subtypes that derive from the MGE. 
 
4.2.3 hESC-derived MGE progenitors can become functional GABAergic neurons 
MGE progenitors differentiated under normoxic conditions were seeded onto coverslips and placed 
in a hypoxic incubator (2% O2) for the remainder of the experiment, due to observed improvements 
in cell adherence and survival compared to normoxic conditions. They were fed with SCM1 medium 
from day 22-30, then SCM2 until day 70, when their activity was recorded. Spontaneous and evoked 
activity was recorded from cells in current clamp mode, once with the cells at their normal resting 
membrane potential, and once more while holding the cells at -60 mV. Cells were filled with Alexa594 
and post-hoc stained for GAD67. 
The mean RMP for all cells was -30 mV (Figure 4.3A). Cells were divided into two groups based on 
whether they fired evoked APs from resting (iAP) or not (nAP). However, no difference was seen in 
mean RMP between the 2 groups. Input resistance also did not differ significantly between iAP and 
nAP cells, and averaged at 255 MΩ (Figure 4.3B). At rest, only 1 cell fired spontaneous APs as well as 
small PSPs, shown in Figure 4.3 (C,D). Four other cells did not fire APs but did receive synaptic 
stimulation evidenced by PSPs. When holding these same cells at a membrane potential of -60 mV, 
however, all but one began firing full APs, often triggered directly by PSPs, which were also larger in 
amplitude. 
All cells were injected with current steps of 10 or 20 pA between -100 and +100 pA. From resting, half 
of cells fired at least 1 AP, the majority of which were “rebound spikes” triggered by hyperpolarising 
negative current. Two cells fired trains of more than 2 APs in succession. When cells were held at -60 
mV, only 2 cells did not fire an AP. Three cells fired AP trains, and 2 more attempted to fire trains. The 
same cell can be seen firing a short train from resting compared to 2 trains of at least 5 APs when held 
at -60 mV (Figure 4.3E). 
Of the 12 cells filled with Alexa594 during recording, only 3 were successfully relocated after staining 
for GAD67. This was likely due to rupturing of the cell membrane during removal of the patch pipette, 
which would have allowed the dye to leak out. However, all 3 cells that were found were stained 
positive for GAD67 (Figure 4.3F). 
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Figure 4.2: MGE progenitors mature into cortical and striatal interneurons. 
A) Cells were fixed on day 60 of MGE and control (no SHH or purmorphamine) differentiation and immunostained 
for somatostatin (SST) and parvalbumin (PV). B) Day 60 MGE differentiated cells were immunostained for 
calretinin (CR), choline acetyltransferase (ChAT), GAD67, Calbindin (CB), NKX2.1 and MAP2. Scale bars: white, 
100 µm; yellow, 20 µm. C) Cells that stained positive for interneuron markers were counted as a percentage of 
DAPI. D) A bar graph comparing the percentage of cells that stained positive for NKX2.1 at days 20 and 60 
(**P<0.01, 1-tailed t-test). Bar graph data show mean ± SEM from n = 2 (PV), 3 (SST), 2 (CR), 3 (NKX2.1 d20), 4 
(NKX2.1 d60) independent experiments respectively.  
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4.3 Discussion 
This chapter has depicted the cell-types generated using an adapted version of the MGE 
differentiation protocol from Maroof et al. (2013). These data have confirmed that hESCs can be 
differentiated to MGE progenitors via Wnt inhibition and SHH activation, and that these can be left to 
mature into GABAergic and cholinergic interneuron subtypes. In medium designed to enhance 
functional maturation of neurons, the cells can begin to show neuronal activity including action 
potentials and post-synaptic potentials. 
At the progenitor stage, a high proportion of cells expressed FOXG1 and NKX2.1 indicating a ventral 
forebrain identity. This was followed by a long in vitro maturation period up to at least day 45, by 
which time some cells had begun to express subtype-specific markers GAD67, somatostatin and 
calretinin. Around day 60, a small proportion of cells also began to express parvalbumin, and the 
proportion of cells expressing NKX2.1 had significantly reduced. This suggests that some cells down-
regulate NKX2.1 expression and are therefore likely to be programmed for cortical interneuron fate. 
The remaining NKX2.1+ cells in the cultures could either be of striatal identity, or simply still be at the 
progenitor stage of differentiation, although the high levels of MAP2 expression would oppose this. 
Maroof et al. used a NKX2.1/GFP reporter hESC line for their study, and so were able to sort GFP-
positive cells on day 32 and plate them onto a mouse cortical feeder layer (Maroof et al., 2013). At 
day 18, around 50% of cells were GFP-positive, slightly less than shown here at day 20. Following 30 
days of co-culture with mouse cortical neurons however, approximately 40% of cells each were SST 
and PV-positive. They did an interesting comparison of the electrophysiology of interneurons cultured 
on mouse cortical feeders versus hESC-derived cortical feeders. With this they showed that the cells 
became more mature at earlier time points on the mouse feeders, perhaps indicating that the speed 
of the mouse neuron maturation may aid in maturing the human interneurons. While the 
electrophysiological data in this chapter shows modest functionality in the absence of feeder cells, 
their cells achieved resting membrane potentials of -66 mV and -45 mV on mouse and human feeders, 
respectively. They also demonstrated the ability to generate fast and long trains of action potentials. 
This shows that the presence of mature neurons and glia may be crucial for achieving useful levels of 
functionality in hPSC-derived neurons. 
Nicholas et al. performed a detailed long term study of the differentiation timeline of their hPSC-
derived interneurons, which they generated using embryoid bodies, the Wnt inhibitor DKK1 and 
purmorphamine (Nicholas et al., 2013). They also made use of a NKX2.1/GFP reporter line, and so 
sorted the cells on day 35 and co-cultured them with mouse glial cells. They obtained 10% PV neurons 
at 15 weeks, but this reduced to 1.5% by 30 weeks and was replaced by SST (40%) and CR-expressing   
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Figure 4.3: hESC-derived MGE progenitors become functional GABAergic neurons. 
A-B) Box plot diagrams comparing the RMP (A) and input resistance (B) of all cells against iAP or nAP cells only. 
Box plots show median with 25th and 75th percentiles (box) and outliers (whiskers), as well as the mean (square) 
from n cells = 14 (all), 9 (iAP) and 5 (nAP) from a single experiment. C) Pie charts showing the proportion of cells 
that displayed spontaneous or evoked activity from their RMP (n=14) or from a holding potential of -60 mV 
(n=12). “Att” = attempted. D-E) Example traces of spontaneous APs and PSPs (D), and voltage responses to 
consecutive current steps (E) each from RMP or -60 mV. F) Representative image of a cell filled with Alexa594 
and post-hoc immunostained for GAD67. 
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cells (77%). Immunostaining for LHX6 allowed them to observe both co-expression with NKX2.1 and 
LHX6+/NKX2.1- cells, which should represent striatal and cortical interneurons respectively, as cortical 
interneurons downregulate NKX2.1 before LHX6 is upregulated on their way to the cortex. This would 
be the easiest way to confirm the presence of striatal interneurons in our cultures, but we have been 
unable to find an antibody that works in our hands. The electrophysiology of the neurons co-cultured 
with mouse glial cells matured dramatically from 8 to 30 weeks of differentiation, with the resting 
membrane potential decreasing from -42 mV to -57 mV and the input resistance reducing from 2 GΩ 
to 0.2 GΩ. The frequency and amplitude of evoked action potentials increased, while the kinetics of 
individual action potentials also became more refined and resembled that of a mature neuron. 
In terms of input resistance, the neurons in this study appear relatively mature compared to those 
presented previously (Maroof et al., 2013; Nicholas et al., 2013), suggesting that they are expressing 
the necessary ion channels to initiate action potentials and respond to synaptic input. However, their 
actual firing patterns are much less mature. This is likely down to the homogeneous nature of these 
cultures, in contrast to co-culture systems, which contain much faster-maturing mouse neurons and 
glia. It would appear from their data that the cells Maroof et al. co-cultured with mouse neurons and 
glia matured more quickly than those Nicholas et al. co-cultured only with glia. This may signify the 
importance of the presence of cortical glutamatergic neurons as well as glia during the maturation of 
cortical interneurons. This theory would also apply to striatal interneurons, which receive 
glutamatergic input from the cortex as well as GABAergic input from striatal MSNs. The cocktail of 
factors and small molecules in the SCM medium devised by Telezhkin et al. for enhanced maturation 
of hPSC-derived neurons may substitute part of what astrocytes provide in terms of what they would 
secrete, but it cannot replace the physical contact that forms the third component of the tripartite 
synapse (Perea, Navarrete and Araque, 2009; Telezhkin et al., 2015). Together, these findings suggest 
that co-culture of hPSC-derived neurons with more mature neurons and glia may be crucial for future 
electrophysiology studies. 
It is interesting that Nicholas et al. showed an initial increase in PV cells followed by almost a complete 
loss of expression (Nicholas et al., 2013). This implies that the PV interneurons may have been lacking 
some form of support to survive, which happened to be present in the cultures of Maroof et al. (2013). 
It would seem logical that PV interneurons are more difficult to produce compared to SST or CR, as 
they appear only postnatally in both the human and rodent brain (Nicholas et al., 2013). However, 
Anderson’s group recently conducted another study in mouse ESCs that has confirmed the possibility 
to enrich for one subtype over another (Tyson et al., 2015). They showed that SST-positive cells are 
derived from MGE progenitors exposed to higher levels of SHH and born early in the differentiation, 
while PV-positive cells are generated later and require lower levels of SHH. Mouse ESCs are known to 
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produce higher levels of endogenous SHH than hESCs, and this was enough to promote differentiation 
into PV interneurons. Translation of this finding into hESC-derived interneurons will require some 
optimisation of SHH concentrations. Furthermore, FACS was used on the mESC-derived MGE 
progenitors to obtain a pure population of Lhx6-positive post-mitotic neural precursors, or NKX2.1-
positive neural progenitors, which produced higher proportions of SST or PV interneurons 
respectively. Use of reporter cell lines for obtaining a pure cell population is suitable for research 
applications, but is not a realistic source of neurons for transplantation therapy. This line of research 
will be of great importance to the field of cell therapy, as PV interneurons appear to play a greater 
role in neurological and psychiatric diseases compared to other subtypes (Hu, Gan and Jonas, 2014). 
This chapter has demonstrated the limited ability of hESCs to differentiate into interneurons in a 
monoculture in vitro. As the intention is to have a source of MGE cells for transplantation as well as 
co-culture systems, the next chapter will describe the outcome of the same cells following 
transplantation into neonatal rat striatum. 
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5 Transplantation of hPSC-derived MGE progenitors into neonatal rat 
striatum 
5.1 Introduction 
As explained in Chapter 4, the MGE gives rise to both cortical and striatal interneurons, as well as 
other forebrain projection neurons. Despite being able to show the generation of MGE-derived 
interneurons from hESCs in vitro, all in vivo studies so far have involved MGE progenitor 
transplantation into cortex or hippocampus (Liu et al., 2013; Maroof et al., 2013). One way to test 
their ability to become striatal interneurons is to transplant the cells as progenitors, directly into the 
striatum of an animal and observe whether they differentiate into relevant interneuron subtypes. 
Use of a GFP-expressing cell line is useful for transplantation studies as a way of easily identifying the 
human cells within host tissue without the need to always use a human-specific antibody. Another 
benefit is the ability to visualise the cells in living tissue, enabling targeted patch clamp recording from 
transplanted neurons to observe their functional properties. Maroof et al. used a NKX2.1/GFP reporter 
hESC line for their study, in which they transplanted MGE progenitors into neonatal mice (Maroof et 
al., 2013). Although they observed minimal GFP down-regulation in their cells and concluded they had 
not matured into PV or SST-expressing interneurons by 8 weeks, they did address that due to the 
natural down-regulation of NKX2.1 in cortical interneurons they would have lost some GFP expression 
over a longer time span, which would have impeded any efforts to easily locate the cells for 
electrophysiology or immunohistochemistry. Denham et al. used a constitutive GFP-expressing hESC 
line and transplanted dorsal forebrain progenitors into neonatal rat striatum (Denham et al., 2012). 
They were able to demonstrate that over 10 weeks, their cells extended long projections through 
white matter tracts and adopted a variety of neuronal morphologies. In addition, they conducted 
patch clamp recording of the cells and showed that 2 out of 4 cells displayed relatively mature 
neuronal firing, both spontaneous and evoked, with evidence of excitatory post-synaptic potentials 
suggesting at least some functional integration. Furthermore, future co-culture or co-transplantation 
of striatal interneurons with MSNs could benefit from distinguishing the 2 cell types by one expressing 
GFP and the other not. 
Allografting studies have provided strong evidence that fate committed neural progenitors can be 
used to replace neurons lost in neurodegenerative disorders such as Parkinson’s and Huntington’s 
disease (Björklund and Stenevi, 1979; Graybiel, Liu and Dunnett, 1989; Klein, Lane and Dunnett, 2012). 
However, for this method to translate to clinical trials, a reliable method of xenografting human tissue 
into animal models for the long term study of its survival, differentiation and functional integration 
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has been vital. Transplantation into neonates is a simple way of observing the capacity of transplanted 
cells to survive, migrate and differentiate in a host brain, and the immaturity of the host immune 
system reduces graft rejection (Rosser, Tyers and Dunnett, 2000; Englund et al., 2002; Eriksson, 
Björklund and Wictorin, 2003; Kallur et al., 2006). As the field has evolved towards trying to generate 
foetal-like tissue from hPSCs, researchers have continued to use neonatal transplantation to 
demonstrate the differentiation and integration potential of cells (Denham et al., 2012; Maroof et al., 
2013). For studies into using cell transplantation as a therapy, graft recipients must be adult disease 
models. Immune suppression of host animals with Cyclosporine A (CsA) was found to highly increase 
xenograft survival and allowed study of human foetal tissue transplants in HD rat models (Brundin et 
al., 1985; Grasbon-Frodl et al., 1997), but over time CsA causes nephrotoxicity that limits the length 
of experiments in rats to around 20 weeks post-transplantation. This may be sufficient to observe 
neuronal survival and differentiation, but real functional integration of human cells is likely to take 
much longer (Espuny-Camacho et al., 2013; Nicholas et al., 2013). The use of immune-deficient 
animals (Nude or SCID), has also become more popular, abolishing the risk of graft rejection by the 
immune system (Samata et al., 2015). However, immune-deficient rodents have a much higher 
susceptibility to infection and must be kept in a pathogen-free environment at all times, making 
facilities more expensive and behavioural studies more difficult to perform. A more recent finding has 
shown that recipient rats can be desensitised to foreign tissue by injecting them with donor cells 
peripherally as neonates (Kelly et al., 2009). Although this technique encountered some initial 
criticism, further research has shown that neonatal desensitisation does not work well in mice, but is 
successful in allowing good survival of human foetal brain-derived cells or hESC-derived neural 
progenitors transplanted into rats until 40 weeks (Janowski et al., 2012; Roberton et al., 2013; Heuer 
et al., 2016). This is much longer than with CsA treatment and leaves the animals in good health for 
the entire experiment. 
The aim of this chapter is to address whether hESC-derived MGE progenitors can become striatal 
interneurons following transplantation into the striatum of neonatal rats. A hESC line that 
constitutively expresses a tau-GFP fusion protein was generated to easily identify the transplanted 
cells during histology and in ex vivo brain slices for electrophysiological recordings. 
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5.2 Results 
5.2.1 Generation of a tau-GFP-expressing hESC line 
The TG4 hESC line was generated as explained in Section 2.1.3. H7 hESCs were transfected with a 
plasmid containing a construct for tau-GFP fusion protein expression and a puromycin resistance 
cassette driven by a constitutive CAG promoter (Figure 5.1A).  TG4 (Tau-GFP cell line 4) cells displayed 
homogeneous GFP expression from the hESC stage and throughout neuronal differentiation (Figure 
5.1B,C). Co-culture of TG4 cells with normal H7 cells allowed for the visualisation of individual cell 
morphology in culture. At day 9 of neuronal differentiation neural rosettes were clearly formed and 
regularly interspaced, by day 21 neural progenitors were migrating out from the rosette core and 
extending longer processes. By day 39, cells were more multipolar and forming structured networks 
of neurons. This cell line was used for all transplantation studies. 
 
5.2.2 Neonatal transplantation does not avoid immune response to xenograft 
Two separate rounds of transplantation were carried out. For both rounds, cells were dissociated on 
day 20 of MGE differentiation and approximately 200,000 cells injected in 1 µl into the right striatum 
of 2-day-old Sprague Dawley pups (Figure 5.2A,D). Pups were placed back with their mothers and 
weaned at around 4 weeks of age. Animals were not given immunosuppressant for the first round, as 
it was thought that transplanting into neonates would avoid immune rejection of the graft. At 4 and 8 
weeks, graft survival was 100% and 50%, respectively (n=2). Maintenance of GFP expression in 
transplanted cells was verified using the human nucleus-specific antibody HuNu. All GFP-positive cells 
stained positive for HuNu, and vice versa (Figure 5.2B). At 16 and 24 weeks, no surviving grafts were 
found. 
There was a strong suspicion that grafts from the first round did not survive due to immune rejection 
of the human cells, therefore a second round of transplantation was carried out with the 
immunosuppressant CsA administered daily (i.p. 10 mg/kg) from weaning onwards. Brains were taken 
at 6, 12 and 20 weeks for histology, and 3 brains were taken at 12 weeks for electrophysiology (Figure 
5.2D). While grafts survived in 3 out of 7 immune suppressed animals at 20 weeks, none of the 5 
untreated rats had surviving grafts, confirming the need for immune suppression in transplantation 
studies using hPSCs. Despite the increased survival rate in the immune suppressed animals, there was 
still a gradual decline in the number of surviving cells as a percentage of the 200,000 transplanted 
cells. At 6 weeks, there was an average of 4.3% cell survival, while at 12 and 20 weeks this had reduced 
to 2.6 and 1.15% respectively (Figure 5.2E).  
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Figure 5.1: Generation of tau-GFP hESC line TG4 
A) Schematic of plasmid used to transfect cells. B) Brightfield and fluorescent image of TG4 hESCs showing 
ubiquitous GFP expression. C) TG4 cells differentiated in co-culture with H7 show cell morphology throughout 
neuronal differentiation. 
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Microglia staining with IBA1 showed a huge increase in the number of microglia in the right, 
transplanted hemisphere of a rat with a rejected graft compared to the left striatum (Figure 5.2C). 
These data show that immune rejection of hESC-derived neural progenitors remains a possibility 
despite transplanting into neonates and administering CsA. 
 
5.2.3 Transplanted hESC-derived MGE progenitors migrate within the first 6 weeks of 
transplantation 
Within the first 6 weeks, cells had migrated from the striatum to the septum and hippocampus in 4 of 
6 animals. It was difficult to know the exact injection site due to brain growth and repair since the 
surgery, so the section in which the majority of cells were found in the striatum, was taken as the 
point of reference for cell migration (Figure 5.3A). By 6 weeks, cells had migrated at least 2.88 mm 
away from the graft core in both anterior and posterior directions, although there was a trend towards 
a greater number of cells migrating posteriorly to the hippocampus. Over time, it appeared that a 
decline in surviving cells lead to a higher proportion of cells close to the graft core and fewer cells 
surviving on their own, especially anteriorly. Although, there were still surviving cells in the septum 
and hippocampus in the majority of animals at 12 and 20 weeks (Figure 5.3B,C). 
Interestingly, cells very rarely entered the cortex, occasionally settling just dorsally to the corpus 
callosum close to the graft core. They did, however, appear to migrate to the dorso-lateral SVZ and 
across to the lateral septum, or ventrally along the SVZ through the pallidum and into the septum, 
from which they could migrate caudally towards the hippocampus (Figure 5.3B). Once in the 
hippocampus, cells concentrated around the CA3 region in the stratum oriens layer, which is home to 
many of the host GABAergic interneurons. 
These data show that transplanted hPSC-derived MGE progenitors can migrate to their normal final 
destination within 6 weeks and settle thereafter.  
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Figure 5.2: Neonatal transplantation does not avoid host immune response and graft rejection 
A) Schematic timeline of MGE differentiation for transplantation, with cells dissociated for grafting on day 20 
and injected into the striatum of neonatal rats. B) Immunostaining for HuNu 4 and 8 weeks post-transplantation, 
showing co-localisation with GFP. C) Timeline for the second round of transplantation, showing the number of 
animals taken for histology or electrophysiology (ephys). D) Table showing the graft survival for each timepoint 
and experiment. E) Immunostaining of brain from 20 weeks with a rejected graft for microglia (IBA1), showing 
left (ungrafted) and right (grafted) striatum.  All scale bars = 100 µm. 
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Figure 5.3: Transplanted cells migrate within the first 6 weeks of transplantation. 
A) HuNu-positive cells were counted in each section (1/12) as a percentage of total HuNu-positive cells, and 
plotted to show the distribution of cells at each time point – 6 (blue), 12 (orange) and 20 (green) weeks. The data 
show mean percentage ± SEM, n = 6, 5 and 3 respectively. B) Tilescan image of a brain section from 12 week old 
rat showing distribution of GFP/HuNu+ cells, including higher magnification of migrating cells (yellow box). C) 
Schematic diagrams of rat brain sections showing the area imaged in (B, red box) and other usual locations of 
GFP/HuNu+ cells in all grafts: striatum, septum, corpus callosum, SVZ and hippocampus. 
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5.2.4 Transplanted hESC-derived MGE progenitors become striatal interneurons 
Brain sections were stained by fluorescent immunohistochemistry to assess the expression of 
interneuron markers by transplanted cells. NKX2.1 was the most abundantly expressed MGE marker 
in the transplanted progenitor population (approximately 80%). Due to the crucial role it plays in 
interneuron migration to either striatum or cortex (and hippocampus), it was hypothesised that 
NKX2.1 expression may differ between cells that had settled in the different brain regions. However, 
NKX2.1 was expressed in 30-36% of HuNu-positive cells at each time point (Figure 5.4A-D), and this 
did not differ significantly between cells in the striatum, septum or hippocampus (data not shown). As 
the proportion of NKX2.1-positive cells did not decrease over the time points, the initial reduction 
from 80% in the transplanted population must have occurred in the first 6 weeks following 
transplantation. 
NeuN, a neuronal marker, was expressed by 50% of cells 6 weeks post-transplantation, and by 49% 
and 56% after 12 and 20 weeks respectively (Figure 5.4A,B,D). These differences were not significant, 
suggesting that by 6 weeks all neural progenitors had differentiated into post-mitotic neurons. Despite 
this, at 20 weeks 44% of cells in one graft still expressed nestin, a neural progenitor marker, indicating 
the maintenance of a progenitor pool that may account for the remaining 44-51% of NeuN-negative 
cells at each time point (Figure 5.4A,D). A good proportion of cells appeared to express GABA or 
GAD67, both GABAergic markers, from 6 weeks onwards, however due to the high positive staining of 
the surrounding striatum and septum, it was not feasible to properly quantify this (Figure 5.4C). 
ChAT, a cholinergic neuron marker, was found to be expressed in a few GFP-positive cells in the 
striatum at 12 and 20 weeks in 3 different grafts, but this was not enough to quantify (Figure 5.4B,C). 
It is worth noting that adjacent sections immunostained for NKX2.1 saw positive staining in cells with 
similar morphology and level of GFP expression to those expressing ChAT. This suggests that the 
GFP/ChAT-positive cells could also be NKX2.1-positive, which would confirm their striatal interneuron 
identity. Surprisingly CR, the subtype marker showing the lowest expression in vitro, was expressed in 
41% and 26% of GFP-positive cells at 12 and 20 weeks respectively (Figure 5.4B-D). CR was widely 
expressed in all brain regions, and actually showed slightly higher expression in the septum and 
hippocampus than in the striatum when the data were separated (data not shown). This is likely to be 
due to the cells in the septum and hippocampus being mature neurons, compared to the graft core in 
the striatum. PV, SST and NPY were not found to be expressed in any GFP-positive cells in any animals. 
There was also no expression of GFAP, a glial marker, in any GFP-positive cells. These data show that 
hESC-derived MGE progenitors can differentiate into CR-expressing or cholinergic striatal, septal and 
hippocampal interneurons in vivo. 
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Figure 5.4: Transplanted MGE progenitors  
differentiate into striatal interneurons. 
A) Graph of quantified markers from immunostaining as a 
percentage of HuNu or GFP-positive cells. B-D) Representative 
images of immunostaining of brain sections from 6 (B), 12 (C) 
and 20 (D) weeks post-transplantation, with GFP-positive 
(green) transplanted cells and DAPI (blue). The brain regions 
depicted are as follows: B) NKX2.1 – striatum, NeuN – 
SVZ/striatum; C) NKX2.1 – striatum, ChAT – striatum, CR – 
hippocampus, NeuN – hippocampus; D) NKX2.1 – SVZ, ChAT – 
striatum, CR – striatum and hippocampus, Nestin – septum, GAD67 – striatum.   
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5.2.5 Transplanted cells adopt region-specific morphologies 
All GFP-positive cells with a visible morphology (i.e. not in clumps) were classified as unipolar, bipolar 
or multipolar and their location recorded (Figure 5.5A). It was hypothesised that neuronal morphology 
would mature over time until the majority or all of the neurons were multipolar but that the rate 
might differ between brain regions. 
Indeed, in the striatum and septum, GFP-positive cells became increasingly complex over time, with 
almost a 1:1:1 ratio at 6 weeks, but more than 73% multipolar cells by 20 weeks and almost no unipolar 
cells present (Figure 5.5B,C). In contrast, the hippocampus had a majority of bipolar cells from 6 
weeks, which was maintained up to 20 weeks, with 78% bipolar cells and only 19% multipolar cells. 
The data show a clear tendency for neurons to develop a multipolar morphology in the striatum and 
septum, whereas a bipolar morphology is maintained in the hippocampus. However, looking at images 
of the cells it is clear that there are other differences between the morphologies of cells that settled 
in different brain regions (Figure 5.5C). Cells in the striatum showed clear maturation between 6 and 
12 weeks from bipolar to multipolar morphology, but the majority still only had 3-5 visible processes. 
In the septum, however, the morphology of the multipolar cells at 12 and 20 weeks was very different 
from those in the striatum, with many processes coming from each soma and a relatively dense 
dendritic tree. The morphology of neurons in the hippocampus appeared to change very little between 
6 and 20 weeks, with very straight, bipolar cells positioned in two strict orientations parallel or 
perpendicular to the adjacent pyramidal cell layer. 
This shows that transplanted cells that settle in different brain regions adopt distinct morphologies, 
however it cannot be discerned whether this is cell autonomous or dependent on the surrounding 
environment. 
 
5.2.6 Patch clamping of transplanted hESC-derived neurons 
At 12 weeks post-transplantation, brain slices were prepared from 3 rats for whole cell patch clamp 
recording of GFP+ cells. Distinct GFP+ cell bodies were found in only one of the brains, from which 3 
cells were patched successfully. Cells were filled with biocytin during recording and post-hoc analysis 
confirmed that all 3 cells were also GFP+ (Figure 5.6A). 
All 3 cells had polarised resting membrane potentials of around -70 mV, however 2 of the cells were 
unresponsive to current injection and showed no spontaneous activity. The third cell had an unstable 
resting membrane potential that averaged at -75 mV (±13 mV), but displayed robust action potential 
76 
 
Figure 5.5: Transplanted MGE progenitors adopt region-specific morphologies. 
A) Examples of unipolar (blue), bipolar (orange) and multipolar (green) GFP-positive cells counted in each region. 
B) Quantification of GFP-positive cells classified as in (A) in the striatum, septum and hippocampus at each time 
point. Data shown are the mean percentage of GFP-positive cells in each category. C) Immunofluorescent images 
of GFP/HuNu-positive (green/red) cells in each region at each time point, with DAPI (blue).  
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firing upon current injection of at least 80 pA, with 120 pA injection triggering a train of action 
potentials (Figure 5.6C,E). Occasional spontaneous firing was also detected, as well as what looked 
like an excitatory post-synaptic current, demonstrating synaptic responsiveness of the cell (Figure 
5.6D). 
Biocytin filling allowed for post-hoc staining with Streptavidin Cy3 conjugate and morphological 
analysis of the functional cell. Partial 3D reconstruction using Neurolucida software showed that the 
cell had a typical neuronal morphology and Sholl profile (Figure 5.6Figure 5.6B). 
 
5.3 Discussion 
In this chapter, I have shown that MGE-like progenitors derived from GFP-expressing hESCs can be 
transplanted into neonatal rats’ brains to produce functional neurons with molecular profiles 
resembling certain striatal interneuron subtypes. I have also presented findings that conflict with the 
general consensus of the underdeveloped neonatal immune system providing a cover behind which 
human cells can hide indefinitely. For my second transplantation experiment, I administered daily 
immunosuppressant CsA in order to get a higher graft survival rate. 
Firstly, generation of a hESC-line expressing tau-GFP was vital for the post-transplantation 
identification of the transplanted cells, particularly because of the migratory nature of both MGE 
progenitors and neonatal grafts (Wichterle et al., 1999). Silencing of transgenes is very common, 
especially in hPSCs and throughout differentiation, so it was important to screen all 4 clones that were 
picked and expanded following transfection and puromycin selection. Of the 4 clones, only one 
maintained GFP expression throughout neuronal differentiation (TG4), and indeed maintained 
expression when transplanted into rat brain. The CAG promoter used here is a constitutive promoter 
that has been shown to drive strong expression in transfected mouse ESCs, increasing at later stages 
of differentiation (Hong et al., 2007). Even within one graft it was clear that some cells were much 
brighter, expressing higher levels of GFP, than others. This shows the importance of screening 
transgenic clones both during routine culture and after differentiation. 
There have been many studies showing long-term survival of human neural tissue transplanted into 
neonatal rats (Englund et al., 2002; Kallur et al., 2006; Zietlow et al., 2012). However, all these studies 
used expanded neural stem cells from human foetal primary tissue. Studies using hPSC-derived neural 
progenitors for transplantation have typically used SCID mice, for both neonatal and adult transplants 
(Liu et al., 2013; Maroof et al., 2013; Nicholas et al., 2013; Cunningham et al., 2014). However, SCID 
mice and their rat counterparts, the athymic nude rat, 
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Figure 5.6: Transplanted hESC-derived MGE progenitors can mature into functional neurons. 
A) Immunostaining of the biocytin-filled cell double-labelled with GFP and located in the anterior dorsomedial 
striatum. B) Biocytin filling allowed for partial reconstruction of the neuron with Neurolucida software and Sholl 
analysis. C) Current injection of 80 pA was sufficient to drive single action potential firing, and 120 pA triggered 
a train of 4 action potentials. D) Spontaneous action potentials were fired in the absence of current injection. E) 
Larger scale version of the action potential train shown in (C), showing the kinetics of the action potentials. 
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are extremely prone to infection and have specific housing requirements that are not always feasible 
to meet. One other study used neonatal Sprague-Dawley rats as recipients for hESC-derived neuron 
transplantation, but only left the grafts for 10 weeks post-transplantation (Denham et al., 2012). The 
authors saw surviving grafts in 13 out of 20 animals transplanted, so it is also possible that over a 
longer time scale the grafts would have been fully rejected. It is very possible that the GFP expression 
causes the cells to be even more immunogenic than the typical foetal tissue grafts. A study showed 
that GFP-positive haematopoietic stem cell (HSC) grafts were rejected far more quickly than HSCs from 
mice with the same genetic background that did not express GFP (Bubnic, Nagy and Keating, 2005). 
Furthermore, a study showed that hESCs (expressing GFP) were rejected from the leg muscle of 
immunocompetent mice within 1 week, and that their survival was extended to 10 days when the 
mice were treated with a rapamycin inhibitor (Swijnenburg et al., 2008). The calcineurin inhibitor, the 
group to which CsA also belongs, did not prolong graft survival past 7 days, although in combination 
with the rapamycin inhibitor it did prolong survival to 14 days. The blood brain barrier makes the brain 
immune-privileged, however the act of transplanting the cells and the neuroinflammatory response 
was found to cause the blood brain barrier to leak for the first 7 days following mouse tissue 
transplantation into rat striatum, allowing entry of peripheral T-lymphocytes (Brundin et al., 1989). 
The dose of CsA used here (10 mg/kg), has typically been enough to keep these T cells at bay and 
prevent xenograft rejection, but on this occasion there was still over 50% loss of grafts at 20 weeks. It 
is likely that human to rat grafts could cause a bigger insult to the blood brain barrier than mouse 
tissue, and it takes longer to develop and express all antigens, prolonging the potential immune 
response. This means that transplanting into neonates may not bypass the immune response as this 
begins to mature after 7-10 days, which is not long enough for the human cells to integrate and the 
blood brain barrier to restore itself (Brundin et al., 1989). As CsA was only given from 4 weeks onwards, 
this also may not be early enough to prevent the immune response from initiating. The IBA1 staining 
presented here was from a CsA-treated rat with a rejected graft, showing that the CsA treatment was 
not sufficient to inactivate the microglia. A big challenge in the transplantation field appears to be the 
variation between findings in different studies, even within the same lab (Brundin et al., 1989). 
Perhaps moving towards the use of immune-deficient mice or rats will be the only way to study the 
true integration and functional potential of hPSC-derived neurons. 
The high level of migration of these MGE-like cells is very similar to that seen previously when 
transplanting foetal MGE tissue into neonatal rat striatum (Wichterle et al., 1999; Englund et al., 
2002). The protocol used for generating MGE-like progenitors in this study was established by Maroof 
et al. and characterised in vitro in the previous chapter (Maroof et al., 2013). In their paper, Maroof 
et al. transplanted cells at differentiation day 32 into mouse neonates and found that after 2 months, 
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cells were still immature, expressing doublecortin and exhibiting uni- or bipolar morphology. In 
contrast, this study transplanted cells after just 20 days of differentiation, at which point there was no 
more expression of pluripotency marker, OCT4, and the vast majority of cells were Nestin and NKX2.1-
positive. Although there was still a lot of nestin expression at 20 weeks, more than half of transplanted 
cells were NeuN-positive from 6 weeks onwards, and more than 25% of cells (half of neurons) had 
undergone subtype specification by 12 weeks to express calretinin. By 12 weeks there were also a few 
cells that had differentiated into cholinergic striatal interneurons. Furthermore, by 6 weeks, the 
NKX2.1-positive population had dropped from 80% at transplantation to 36%. This is in stark contrast 
to the previous study, which found that all transplanted cells were still expressing NKX2.1 and GFP, 
and that none of them had differentiated into any interneuron subtype (Maroof et al., 2013). 
Curiously, very few transplanted cells settled in the cortex, and in many subjects only cell debris could 
be seen in the cortex, likely from cells being deposited along the needle tract, compared to healthy-
looking cells in the striatum, septum and hippocampus. This finding cannot really be explained, as 
many groups have reported successful transplantation of MGE foetal tissue or hPSC-derived either 
directly into the cortex or that has actually migrated there from the striatum or lateral ventricle 
(Wichterle et al., 1999; Nicholas et al., 2013; Wang et al., 2016). Despite this, the finding that more 
than a quarter of transplanted cells differentiated into CR interneurons is promising, as these are an 
important interneuron subtype. The majority of CR-expressing interneurons are thought to derive 
from the CGE, the caudal neighbour to the MGE, which does not express NKX2.1 at progenitor stage 
and is instead identified by COUP-TFII expression (Kanatani et al., 2008). Nonetheless, Marin et al. 
reported that 94% of CR cells in the striatum of adult mice co-expressed NKX2.1, and that NKX2.1 
mutants saw a six fold reduction in the number of CR interneurons (Marin, Anderson and Rubenstein, 
2000). It is possible, then, that the majority of CGE-derived CR interneurons migrate to the cortex, 
while MGE-derived CR interneurons settle in the striatum. Indeed, it was recently shown that in 
human and primate striatum, nearly all striatal interneurons originate from the MGE and express 
NKX2.1 (Wang et al., 2014). Crucially, primate CR interneurons form a much higher proportion of 
striatal neurons as a whole, as well as within the interneuron population, than in rodents. Rat 
GABAergic interneurons comprise only 4-5% of striatal neurons, with predominantly PV interneurons 
in comparison to CR or SST. In contrast, human and primate GABAergic interneurons make up 23% of 
striatal neurons, with around three times more CR interneurons than PV or SST (Wu and Parent, 2000). 
This difference cannot be overstated, and indeed is often overlooked when discussing striatal 
interneuron research conducted in rodents for the purposes of understanding human biology. 
Perhaps the cells at day 20 of differentiation are plastic enough that their subtype specification is still 
undecided. Sister cultures left to mature in vitro produced more PV and SST cells than CR (Chapter 4), 
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but when transplanted into neonatal rat striatum the only subtype to appear was CR. As 40% of 
transplanted cells became CR interneurons, whereas only approximately 16% of cells in vitro matured 
into any specific interneuron subtype, it would appear that the cells maturing in vitro may be lacking 
environmental cues to fully differentiate that were present in the neonatal rat brain. Future studies 
of this nature should address transplantation of more mature cells at later differentiation points to 
see if this changes their subtype specification in vivo. Another key factor may be the age and level of 
neurodegeneration of the recipient brain. Transplanting the same cells into the adult rat lesioned 
striatum may bias them towards a different interneuron subtype or encourage outgrowth and 
integration. Indeed, hESC-derived neuronal maturation has been shown to be accelerated in lesioned 
striatum compared with intact neonatal transplantation (Joannides et al., 2007). Furthermore, 
migration of transplanted MGE-like cells was less extensive in intact adults compared to neonatal 
recipients in the Maroof et al. study, and mesencephalic stem cells have been shown to differentiate 
faster in 6-OHDA lesioned than intact striatum (Nishino et al., 2000; Maroof et al., 2013). These 
differences could prove crucial for clinical transplantation and will need thorough assessment before 
progression towards trials in humans. 
The transplanted cells acquired very distinct morphologies depending on the brain region in which 
they settled. NKX2.1 is the only known migratory regulator whose expression was analysed in the 
different brain regions, but there was no difference in its expression between cells in the striatum, 
septum or hippocampus. This means that we cannot conclude whether the cells migrated purposefully 
to their destinations and acquired, for example, a hippocampal CR interneuron morphology because 
they were intrinsically programmed to do so, or whether this occurred as a result of exogenous cues 
after finding themselves in the hippocampus. In normal mammalian development, MGE progenitors 
destined for the hippocampus would down-regulate NKX2.1 before migrating through the cortex to 
end up in the hippocampus (Marin, Anderson and Rubenstein, 2000). In this study, however, they 
appear to have migrated either through the septum or the globus pallidus to reach the hippocampus, 
many maintaining NKX2.1 expression. Many of the cells that settled in the lateral septal nucleus had 
a very unique morphology that differed from any other GFP-positive cells seen in the brain. They had 
a very complex stellate shape, were mostly NeuN-positive and all GFAP-negative. None of the 
molecular markers apart from NKX2.1 or NeuN were expressed in these cells, so despite their specific 
morphology they did not adopt the fate of the majority of septal neurons, which is a GABAergic CR 
fate (Zhao, Eisinger and Gammie, 2013). Further characterisation will be necessary to identify these 
cells. 
Finally, the constitutive GFP expression in the transplanted cells allowed for visualisation in ex vivo 
brain slices for whole cell patch clamp analysis of the cells’ membrane properties and firing 
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characteristics. Although GFP expression alone was sufficient to see the cells following fixation and 
immunohistochemical staining of 40 µm thick sections, in 300 µm sections used for electrophysiology, 
it was apparently much more difficult to see the GFP. This meant that of three brains taken for 
electrophysiology at 12 weeks, only three cells were found in two sections of one of the brains. 
However, one of these cells did show some promising characteristics, in that it had a polarised resting 
membrane potential and fired large action potentials both spontaneously and when stimulated. This 
is a similar level of functionality to what Denham et al. saw in their study at 10 weeks post-
transplantation (Denham et al., 2012). Nicholas et al. left their cells to mature for 7 months in SCID-
mice cortices, and saw a much more mature electrophysiological profile, suggesting that the 
maturation of hPSC-derived neurons resembles that of neurons developing in the human brain 
(Nicholas et al., 2013). The thickness of the section used for electrophysiology allowed for a more 
comprehensive view of the cell’s morphology compared to the sections made for histology. Biocytin 
filling of the cell therefore allowed for a partial reconstruction of the cell, which was relatively complex 
possessing 7 primary processes. 
In this chapter, the data presented have shown that hESC-derived MGE progenitors can differentiate 
and mature in vivo into striatal, septal and hippocampal interneurons. Although they appear to be 
limited to a CR fate when transplanted into the striatum, the cells appear to be adaptable to their 
environment and it may be possible to push them towards a more PV or SST fate by altering the time 
windows for transplantation or the age of the animals. It will be important for future transplantation 
studies to achieve a standard procedure to enable long term maturation of hPSC-derived neuron grafts 
if these cells are ever to be taken into clinical trials. 
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6 General discussion 
6.1 Summary 
This thesis has reported findings that demonstrate the possibility of generating functional striatal 
neurons in vitro from hPSCs. Two published protocols were used, one to produce striatal projections 
neurons, or MSNs, developed in our lab, and another to derive GABAergic and cholinergic striatal 
interneurons (Maroof et al., 2013; Arber et al., 2015). Investigation into the mechanism of the MSN 
differentiation uncovered a potential novel role for BMP signalling in MSN development, and it has 
been shown for the first time that hPSC-derived MGE progenitors can produce striatal-specific 
interneurons rather than cortical or hippocampal interneurons, which have already been heavily 
studied (Liu et al., 2013; Maroof et al., 2013; Nicholas et al., 2013; Cunningham et al., 2014). In 
addition, the advantages of deriving and using a hESC-line with constitutive GFP expression for 
transplantation studies have been highlighted. 
In the process of working towards the aim of generating functional striatal neurons, many of the 
applications for which hPSCs can be useful have been portrayed. By investigating the mechanism via 
which Activin induces LGE and MSN fate, a potential novel pathway in MSN specification has been 
discovered, showing how directed differentiation of hPSCs can aid in studying human development. 
Secondly, electrophysiological data from both types of striatal neurons has been presented, showing 
that their functionality can be improved by culturing them in more physiologically and 
developmentally relevant media (Telezhkin et al., 2015). This will be crucial in future studies aiming to 
model functional development of the striatum as well as analysing disease cell models for changes in 
their membrane and synaptic properties. Finally, the last chapter has established that transplantation 
of the hPSC-derived MGE progenitors into neonatal rat striatum could push the cells to favour a 
calretinin interneuron fate when compared to the sister cultures in vitro. This highlights the 
importance of transplantation studies in this field for the purpose of observing the differentiation 
potential of hPSC-derived neurons. It also shows the possibility of transplanting GFP-expressing cells 
for electrophysiological analysis, which will be crucial for proving true functional integration of 
transplanted neurons in a host brain. 
6.2 Implications for the study of human development 
There are many stages to striatal development that can be clearly defined and modelled through hPSC 
differentiation. The procedure for generating both striatal cell types exploited the dual Smad inhibition 
monolayer neural induction method proposed by Chambers et al. (2009). This is a reliable and straight 
forward technique of efficiently pushing hPSCs towards a forebrain lineage within 10 days. Our lab has 
a wealth of experience working on directed monolayer differentiation of mouse and human ESCs 
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towards neurons of diverse subtypes (Jaeger et al., 2011; Cambray et al., 2012; Arber et al., 2015). The 
monolayer method has several advantages over 3D differentiation methods, such as embryoid bodies 
or organoids, in that all cells are uniformly exposed to the culture medium and patterning factors, 
resulting in a more synchronised and therefore homogeneous neuronal population. There is no need 
for mechanical selection, and the entire process can be done in a fully defined and xeno-free 
environment making it easier to scale up for future clinical purposes. 
The next stage involves patterning of the neural progenitors towards a particular neuronal lineage, 
namely striatal neurons. This is the step represented by the Activin or SHH treatment , which aims to 
produce as a high a proportion of the desired cell type as possible (Maroof et al., 2013; Arber et al., 
2015). At this stage, much work has already been done to optimise the concentration and timing of 
patterning factors to produce a homogeneous population, but more research could be done to enrich 
them further. In addition, the mechanism of induction is not always well-defined, and while the 
presence of Smads and Activins in the developing striatum was previously known, the developmental 
mechanism by which Activin induces LGE fate remains unclear (Maira et al., 2010). In this thesis, I have 
presented evidence showing that Activin exerts its effects independently of the SHH pathway, which 
was the pathway previously exploited for the production of MSNs (Aubry et al., 2008; Ma et al., 2012; 
Carri et al., 2013; Nicoleau et al., 2013). Furthermore, in an attempt to elucidate the mechanism of 
Activin, I have discovered a novel pathway that appears to play a role in MSN differentiation, BMP 
receptor inhibition. Future experiments in this area will focus on the actions of phosphorylated 
Smad2/3, Activin’s intracellular effector, and its effects on gene transcription. Another logical next 
step would be to look in vivo, and whether Activin and BMP signalling play an instructive role in MSN 
fate specification in rodent striatal development. In this way, preliminary studies and high throughput 
screening on hPSC differentiation allow more hypothesis-driven in vivo experiments, reducing the 
number of animals used in research. 
In contrast, the mechanism by which SHH induces MGE fate by NKX2.1 upregulation is somewhat 
better understood (Gulacsi and Anderson, 2006). NKX2.1 is expressed throughout the entire ventral 
neural tube, though co-expression with the forebrain marker FOXG1 is vital for MGE specification. 
Stewart Anderson’s group have done much work to optimise the timing of Wnt inhibition for forebrain 
promotion, and SHH activation, showing that earlier SHH treatment encourages a more caudal fate 
resulting in hypothalamic-like progenitors, while later addition of SHH promotes a GABAergic 
interneuron fate (Maroof et al., 2013). This work also demonstrates how research on hPSCs has a 
mutually beneficial relationship with in vivo developmental research, as hPSCs provide a more easily 
manipulable model on which to test different conditions, while in vivo studies give an insight into the 
brain developing as a whole within an organism. Crucially, hPSCs, unlike mouse ESCs, offer an 
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unprecedented bridge between rodent studies and live human development, as human brain tissue is 
sparse and difficult to standardise. 
The final stage of in vitro differentiation is neuronal maturation – the cells have been patterned 
towards the cell type of choice, then they are typically left to mature in a basal differentiation medium 
containing neurotrophic factors. This is now a stage that can begin to be optimised and used as a 
model of development and function for the specific brain region being studied. In other words, the 
organisation, physiology and synaptic connectivity of hPSC-derived MSNs and striatal interneurons 
can be studied as they mature as a model of striatal development. For this, it is likely that novel culture 
systems will need to be devised for co-culturing MSNs, interneurons and glial cells, as well as 
innervating cells such as cortical pyramidal and midbrain dopaminergic neurons or target cells such as 
pallidal projection neurons. Studies using mouse embryonic neurons have demonstrated the 
importance of  co-cultures including cortical neurons in co-culture with MSNs in order to achieve an 
in vivo-like morphology with mature dendritic spines (Penrod et al., 2011). Reporter cell lines would 
also be invaluable to this line of research, not only to distinguish between, for example, hPSC-derived 
interneurons that are co-cultured with MSNs, but also to be able to identify interneuron subtypes 
within the heterogeneous population of cells produced using the MGE protocol. This would allow 
much more targeted experiments, particularly for electrophysiology, without the need to analyse 
undesired cell types and retrospectively identify them using post-hoc staining. 
6.3 Implications for disease modelling 
Just as each differentiation step can model the stages of development in physiological conditions. 
There are many neurological and neuropsychiatric conditions that carry a developmental component. 
Indeed, there is evidence that HD affects foetal and childhood brain development, despite not typically 
becoming symptomatic until middle age (Nopoulos et al., 2011; Lee et al., 2012). Previous work on HD 
iPSCs have been carried out using heterogeneous cell populations with a relatively low proportion of 
DARPP32-positive MSNs, but have already found HD-induced changes in cell metabolism, adhesion 
and death (Zhang et al., 2010; The HD iPSC Consortium, 2012). ASD and schizophrenia are known 
neurodevelopmental disorders caused by a complex interaction between genes and the environment. 
Despite a huge amount of research into cortical and hippocampal dysfunction in these disorders, there 
is also strong evidence for a striatal role in the cognitive and repetitive behavioural deficits 
experienced (Simpson, Kellendonk and Kandel, 2010; Fuccillo, 2016). Having devised a robust protocol 
for generating MSNs, and here shown that we can also produce striatal interneurons from hPSCs, our 
future research plan is to apply these methods to HD, ASD or schizophrenia patient-derived iPSCs to 
look at more striatal-relevant phenotypes. Perhaps an ultimate test of the authenticity of hPSC-
derived MSNs would be their relative vulnerability compared to neurons of other types derived from 
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HD patient iPSCs. Again, hPSCs provide a bridge between in vivo studies or work done on rodent in 
vitro models and human disease. 
Induced neurons are another source of living human neurons that may hold greater promise for 
patient-specific studies, such as personalised medicine. They provide a fast and effective way of 
obtaining a high proportion of MSNs or interneurons from patient fibroblast biopsies, which would 
allow screening of potential drugs for a specific patient (Victor et al., 2014; Colasante et al., 2015). 
However, the direct conversion of the fibroblasts into neurons avoids the neural progenitor stage 
missing the opportunity for expansion and limiting the yield considerably. Human PSC-derived LGE 
and MGE progenitors can be easily frozen in bulk and then thawed as needed, generating MSNs or 
interneurons within 3 or 6 weeks respectively. Furthermore, hPSCs allow genetic manipulation of 
potential downstream targets of HD, such as CTIP2 (Desplats, Lambert and Thomas, 2008). Our lab has 
recently established multiple cell lines either with tamoxifen-inducible overexpression or 
heterozygous or homozygous knockout of CTIP2. Studies like this aid in the dissection of disease 
mechanisms, and are also being applied for candidate genes in schizophrenia and ASD discovered in 
genome-wide association studies. As these are polygenic diseases with no single cause, specific genes 
can be manipulated in hPSCs to investigate their cellular function and therefore how they cause a 
disease phenotype (Williams et al., 2011; Chen et al., 2015). The ability to specify the hPSCs towards 
a particular cell type widens the opportunities for complex co-culture systems with which to model 
these diseases. 
6.4 Implications for regenerative medicine 
The findings presented here do not directly address the issue of cell replacement therapy, as 
transplantation was only carried out in intact neonatal rats as opposed to an adult disease model. 
However, they did highlight some technical obstacles delaying progress in the field. Firstly, 
transplantation of hPSC-derived neural progenitors into neonatal rats does not appear to prevent 
immune rejection of the graft, nor does daily immunosuppressant administration guarantee it. In 
addition, 20 weeks is not sufficient time for all human cells to mature into neurons, nor for those that 
do to become fully functionally integrated (Nicholas et al., 2013). The workload and timeline for these 
experiments is very heavy, and so a more reliable method must be considered for future studies. Nude 
rats may provide the necessary incubation time for neonatal or intact animal experiments to observe 
the differentiation and integration potential of cells, but their susceptibility to infection and illness 
makes behavioural experiments very difficult to conduct. Instead, neonatal desensitisation may be a 
more viable option for disease models and behavioural studies, as no immune suppression is required 
and can allow graft survival to at least 40 weeks (Kelly et al., 2009; Heuer et al., 2016). Another 
important consideration when transplanting hPSC-derived neural progenitors is their level of fate 
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commitment and the extent to which the host brain environment may influence and fine tune their 
differentiation. This was made clear in the experiment presented here, where sister cultures left to 
mature in vitro produced quite different interneuron subtypes than those in the grafts, although they 
could all be considered of MGE identity. 
6.5 Conclusions 
The findings presented in this thesis support the use of hPSCs in the generation of specific neuronal 
subtypes for studying neural development, disease modelling and transplantation studies for cell 
replacement therapy. These types of studies have gained a lot of momentum over the recent years, 
and the ability to produce functional striatal neurons allows much more directed experiments into 
striatal development and function, rather than studying undefined heterogeneous populations of 
neurons. The ability to generate iPSCs from patient somatic cells also opens up a wealth of possibilities 
for personalised research and medicine in the future. 
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